Page last updated: 2024-11-04

halothane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID3562
CHEMBL ID931
CHEBI ID5615
SCHEMBL ID25588
MeSH IDM0009773

Synonyms (142)

Synonym
gtpl2401
1,1,1-trifluoro-2-bromo-2-chloroethane
2-bromo-2-chloro-1,1,1-trifluoroethane
1,1,1-trifluoro-2-chloro-2-bromoethane
CHEBI:5615 ,
1-bromo-1-chloro-2,2,2-trifluoroethane
2,2,2-trifluoro-1-chloro-1-bromoethane
phthorothanum
rhodialothan
ethane, 2-bromo-2-chloro-1,1,1-trifluoro-
NCGC00090868-01
halothanum [inn-latin]
ccris 6244
halotano [inn-spanish]
ftorotan [russian]
alotano
narcotann ne-spofa [russian]
bromchlortrifluoraethanum
halothane [anaesthetics, volatile]
hsdb 6753
freon 123b1
chalothane
ethane, 2-bromo-2-chloro-1,1,1-trifluoro-, (+-)-
2-brom-2-chlor-1,1,1-trifluorethan
(+-)-2-bromo-2-chloro-1,1,1-trifluoroethane
ethane, 1-bromo-1-chloro-2,2,2-trifluoro-
alotano [dcit]
nsc 143490
einecs 205-796-5
brn 1736947
151-67-7
C07515
HALOTHANE ,
ftuorotan
narkotan
wln: gyexfff
nsc-143490
halan
narcotan
halotan
fluorotane
halotano
narcotane
2,2-trifluoro-1-chloro-1-bromoethane
ftorotan
1,1-trifluoro-2-bromo-2-chloroethane
1,1-trifluoro-2-chloro-2-bromoethane
bromochlorotrifluoroethane
ethane,1,1-trifluoro-
halsan
2-bromo-2-chloro-1,1-trifluoroethane
fluothane
halothan
fluktan
nsc143490
anestan
2-bromo-2-chloro-1,1,1-trifluoroethane, >=99%
DB01159
D00542
fluothane (tn)
halothane (jp17/usp/inn)
HMS2094K17
halothanum
CHEMBL931 ,
bdbm50112212
inchi=1/c2hbrclf3/c3-1(4)2(5,6)7/h1h
bcqzxomgpxttic-uhfffaoysa-
NCGC00090868-02
NCGC00090868-03
halothane [usp:inn:ban:jan]
uqt9g45d1p ,
narcotann ne-spofa
unii-uqt9g45d1p
NCGC00258404-01
tox21_200850
AKOS006227959
nsc760138
nsc-760138
pharmakon1600-01505434
cas-151-67-7
tox21_111033
dtxsid4025371 ,
dtxcid605371
S4570
cf3chclbr
FT-0626853
EPITOPE ID:150925
halothane [orange book]
halothane [usp monograph]
halothane [green book]
halothane [inn]
halothane [ep impurity]
halothane [mart.]
halothanum [who-ip latin]
halothane [ep monograph]
(+/-)-2-bromo-2-chloro-1,1,1-trifluoroethane
halothane [vandf]
halothane [who-dd]
ethane, 2-bromo-2-chloro-1,1,1-trifluoro-,(+/-)-
halothane [who-ip]
halothane [mi]
halothane [hsdb]
halothane [jan]
CCG-213438
SCHEMBL25588
NCGC00090868-05
tox21_111033_1
1-bromo-1-chloro-2,2,2-trifluorethane
CS-4523
(.+/-.))-halothane
HY-B1010
AB01563314_01
mfcd00009602
sr-05000001969
SR-05000001969-1
halothane, united states pharmacopeia (usp) reference standard
2-bromo-2-chloro-1,1,1-trifluoroethane, >=99.0% (gc)
halon 2311
H11280
EN300-90288
ethane, bromochlorotrifluoro-
2,2,2-trifluoro-1-bromo-1-chloroethane
J-008834
SBI-0206928.P001
Q32921
HMS3885H08
NCGC00090868-06
Z1201617125
halothane (mart.)
halothane (ep impurity)
halotano (inn-spanish)
fluothane, halothane, usp
halothanum (latin)
halothane (ep monograph)
halothane (usp monograph)
n01ab01
halothane (usp:inn:ban:jan)
1,1,1-trifluoro-2,2-chlorobromoethane
fluotane
halothanum (inn-latin)
(2rs)-2-bromo-2-chloro-1,1,1-trifluoroethane
r 123b1

Research Excerpts

Overview

Halothane (Fluothane) is a halogenic volatile anaesthetic used in therapeutic since 1956. Halothane is a more potent bronchodilator of the small airways than isoflurane.

ExcerptReferenceRelevance
"Halothane is a more potent bronchodilator of the small airways than isoflurane."( Allergen challenge during halothane compared to isoflurane anesthesia induces a more potent peripheral lung response.
Borges, MC; Ludwig, MS; Marchica, CL; Narayanan, V, 2013
)
1.41
"Halothane is a model volatile anesthetic known to impact functions of model lipid bilayers, altering the structure and thickness upon its partitioning from the bulk phase."( Halothane solvation in water and organic solvents from molecular simulations with new polarizable potential function.
Johannes, J; Lev, B; Noskov, SY; Subbotina, JO, 2010
)
2.52
"Halothane is a widely used anesthetic in research. "( On the use of isoflurane versus halothane in the study of visual response properties of single cells in the primary visual cortex.
Casanova, C; Villeneuve, MY, 2003
)
2.05
"Halothane (Fluothane) is a halogenic volatile anaesthetic used in therapeutic since 1956. "( [Halothane-induced hepatitis. 8 case reports].
Belkahia, C; Daghfous, M; Daghfous, R; el Aïdli, S; Kastalli, S; Loueslati, MH; Sfaxi, M; Sraïri, S, 2003
)
2.67
"Halothane is an important human and veterinary anesthetic, which produces free radicals during biotransformation. "( Effects of vitamin C on liver enzymes and biochemical parameters in rats anesthetized with halothane.
Aydilek, N; Cay, M; Hayat, A; Karakilçik, AZ; Zerin, M, 2005
)
1.99
"Halothane is an effective bronchodilator and inhibits airway smooth muscle contraction in part by inhibiting intracellular signaling pathways activated by the M2 muscarinic receptor and its cognate inhibitory heterotrimeric guanosine-5'-triphosphate (GTP)-binding protein (G protein), Gi. "( Effect of halothane on galphai-3 and its coupling to the M2 muscarinic receptor.
Jin, F; Jones, KA; Penheiter, AR; Penheiter, SG; Spencer, JD; Streiff, JH; Wang, S; Warner, DO, 2005
)
2.17
"Halothane is a volatile anaesthetic, which is known to induce alterations in cellular plasma membranes, modulating the physical state of the membrane lipids and/or interacting directly with membrane-bound proteins, such as integrin receptors. "( Halothane affects focal adhesion proteins in the A 549 cells.
Altankov, G; Hristova, K; Momchilova, A; Pankov, R; Stephanova, E; Valtcheva-Sarker, R, 2007
)
3.23
"Halothane is a well known cerebral vasodilator that can produce dangerous increases in intracranial pressure (ICP) in certain neurosurgical patients. "( A comparison of the cerebrovascular and metabolic effects of halothane and isoflurane in the cat.
Drummond, JC; Todd, MM, 1984
)
1.95
"Halothane is an inhalation anesthetic with potent bronchodilator properties."( Halothane in status asthmaticus.
Crone, RK; O'Rourke, PP, 1982
)
2.43
"Halothane appeared to be a major stimulus to pituitary adrenocortical activation because the adrenocortical secretion was proportional to the amount of halothane inhaled."( Pituitary-adrenal activity and opioid release in ponies during thiopentone/halothane anaesthesia.
Luna, SP; Taylor, PM, 1995
)
1.24
"Halothane is a potent bronchodilator. "( Inhibitory effects of halothane on high(K+)-induced canine tracheal smooth muscle contraction and intracellular Ca2+ increment.
Kawamata, T; Kohro, S; Namiki, A; Yamakage, M, 1994
)
2.05
"Halothane is a potent bronchodilator that attenuates vagally mediated constriction of canine airways, in part by a direct action on the smooth muscle cell. "( Halothane alters cytosolic calcium transient in tracheal smooth muscle.
Housmans, PR; Jones, KA; Lorenz, RR; Rehder, K; Warner, DO, 1993
)
3.17
"Halothane is a poor anesthetic during fetal intervention."( Halothane as an anesthetic for fetal surgery.
Assad, RS; Hanley, FL; Sabik, JF, 1993
)
2.45
"Halothane is a potent dilator of cerebral arteries. "( Halothane-induced dilatation of intraparenchymal arterioles in rat brain slices: a comparison to sodium nitroprusside.
Farber, NE; Harkin, CP; Hudetz, AG; Kampine, JP; Schmeling, WT, 1997
)
3.18
"Halothane is a strong inhibitor of potassium evoked spreading depression (SD) in cats. "( Reduction of infarct volume by halothane: effect on cerebral blood flow or perifocal spreading depression-like depolarizations.
Fujita, T; Graf, R; Heiss, WD; Hübel, K; Rosner, G; Saito, R, 1997
)
2.03
"Halothane hepatitis is a paradigm for immune mediated adverse drug reactions."( Halothane hepatitis.
Neuberger, J, 1998
)
2.46
"Halothane was found to be a significantly more potent vasodilator of the isolated basilar artery than was isoflurane."( A comparison of the vasodilating effects of halothane and isoflurane on the isolated rabbit basilar artery with and without intact endothelium.
Jensen, NF; Kramer, DJ; Leonard, PA; Todd, MM; Warner, DS, 1992
)
1.27
"Halothane is a frequently used agent. "( Advantages and guidelines for using halothane.
Short, CE, 1992
)
2
"Halothane is a potent inhaled anesthetic that is used extensively in veterinary practice. "( Precautions when using halothane.
Gleed, R, 1992
)
2.04
"Halothane was found to be an acceptable alternative to chloroform for removing gutta-percha and sealer from the obturated root canal."( Effectiveness of halothane used with ultrasonic or hand instrumentation to remove gutta-percha from the root canal.
Campbell, AD; Hicks, ML; Ladley, RW; Li, SH, 1991
)
1.34
"Halothane was shown to be a weaker agent than enflurane with respect to the ability to displace drugs from serum proteins and liver cytosol."( Binding and distribution of restrictively and non-restrictively eliminated drugs to serum and liver cell cytosol: effects of volatile anaesthetics.
Dale, O; Nilsen, OG, 1986
)
0.99

Effects

Halothane has a direct action on vascular smooth muscle cells and causes relaxation of these cells, yet neither the mechanism nor the site of its action is completely understood. It has a reversible inhibition of sodium-calcium exchange current in neonatal myocardium.

Halothane has been shown to produce significant changes in heart rate and strength of contraction. Halothane hepatitis has occurred, treatment is purely supportive with the possibility of transplantation for those in grade IV encephalopathy.

ExcerptReferenceRelevance
"Halothane has a direct effect in rendering the Transoxode inaccurate, which is probably clinically less important than the indirect cardiovascularly medicated influence of both halothane and enflurane on TcPO2 levels."( An evaluation of the Hellige Transoxode (Servomed Oxymonitor SM 361 System): response to halothane and enflurane in vitro.
Brock-Utne, JG; Downing, JW; Holloway, AM; Mankowitz, M, 1981
)
1.21
"Thus halothane has a reversible inhibition of sodium-calcium exchange current in neonatal myocardium."( Sodium-calcium exchange in neonatal myocardium: reversible inhibition by halothane.
Baum, VC; Wetzel, GT, 1994
)
0.98
"Halothane has a direct action on vascular smooth muscle cells and causes relaxation of these cells, yet neither the mechanism nor the site of its action is completely understood. "( The effects of halothane on arginine-vasopressin-induced Ca2+ mobilization from the intracellular stores and the receptor-mediated Ca2+ entry from the extracellular space in single cultured smooth muscle cells of rat aorta.
Fujihara, H; Fujiwara, N; Fukuda, S; Shimoji, K, 1996
)
2.09
"Halothane has an effect at the endothelial receptor level, but not any distal steps in the NO-cGMP pathway."( Isoflurane and halothane attenuate endothelium-dependent vasodilation in rat coronary microvessels.
Dai, HB; Darvish, A; Lowenstein, E; Park, KW; Sellke, FW, 1997
)
1.37
"The halothane has various effects upon the heart: reduces the cardiac frequency, reduces the conduction speed of the cardiac impulse stimulating rhythm disorders, sensitizes the myocardium to the action of adrenaline, diminishes the heart's contraction force and the cardiac flow."( [Neosynephrine mydriasis combined with general anesthesia with halothane in ocular surgery].
Giuri, S, 2002
)
1.04
"Halothane has been reported to sensitize Ca(2+) release from the sarcoplasmic reticulum (SR), which is thought to contribute to its initial positive inotropic effect. "( Antagonistic actions of halothane and sevoflurane on spontaneous Ca2+ release in rat ventricular myocytes.
Graham, MD; Harrison, SM; Hopkins, PM, 2006
)
2.08
"Halothane has dual action on FSR: the Ca release and the inhibition of Ca uptake."( The Ca-releasing action of halothane on fragmented sarcoplasmic reticulum.
Kurebayashi, N; Ogawa, Y, 1982
)
1.28
"Halothane has a direct effect in rendering the Transoxode inaccurate, which is probably clinically less important than the indirect cardiovascularly medicated influence of both halothane and enflurane on TcPO2 levels."( An evaluation of the Hellige Transoxode (Servomed Oxymonitor SM 361 System): response to halothane and enflurane in vitro.
Brock-Utne, JG; Downing, JW; Holloway, AM; Mankowitz, M, 1981
)
1.21
"Halothane has been extensively investigated and it was found that up to 0.8% halothane could be administered during cesarean section without an increase in blood loss."( Anaesthesia for termination of pregnancy.
Grant, IS, 1980
)
0.88
"Halothane has been shown to attenuate NO-mediated cyclic guanosine monophosphate accumulation in neurons, and a variety of anesthetic agents attenuate endothelium-mediated vasodilation, suggesting an interaction of anesthetic agents and the NO-cyclic guanosine monophosphate pathway."( Selective anesthetic inhibition of brain nitric oxide synthase.
Breslow, MJ; Martin, LD; Tobin, JR; Traystman, RJ, 1994
)
1.01
"Halothane has been reported to inhibit NO induced relaxation."( Effects of halogenated and non-halogenated anesthetics on diaspirin cross-linked hemoglobin induced contractions of porcine pulmonary veins.
Bina, S; Hart, JL; Jing, M; Ledvina, MA; Muldoon, SM, 1995
)
1.01
"Halothane has been reported to possess a catecholamine-sensitizing effect in laboratory animals and in anesthetized patients and to enhance the positive inotropic effect of isoproterenol in human papillary muscle strips. "( Interaction of halothane with inhibitory G-proteins in the human myocardium.
Böhm, M; Schmidt, U; Schwinger, RH, 1995
)
2.09
"Halothane has endothelium-independent vasoconstricting and vasodilating actions in isolated mesenteric resistance blood vessels. "( Endothelium-independent vasoconstricting and vasodilating actions of halothane on rat mesenteric resistance blood vessels.
Boyle, WA; Maher, GM, 1995
)
1.97
"Halothane has been previously shown in vitro to decrease both the inward calcium current in isolated cells and the density of calcium antagonist binding sites in cardiac sarcolemmal membranes prepared from several species, including humans, presumably contributing to the negative inotropic effects seen with volatile anesthetics. "( The effects of halothane on voltage-dependent calcium channels in isolated Langendorff-perfused rat heart.
Blanck, TJ; Lee, DL; Zhang, J, 1994
)
2.08
"Halothane has been reported to sensitize the myocardium towards the effects of exogenous catecholamines in patients and laboratory animals. "( Sensitization of adenylate cyclase by halothane in human myocardium and S49 lymphoma wild-type and cyc- cells: evidence for inactivation of the inhibitory G protein Gi alpha.
Böhm, M; Böhm, S; Erdmann, E; Gierschik, P; Schmidt, U; Schwinger, RH, 1994
)
2
"Thus halothane has a reversible inhibition of sodium-calcium exchange current in neonatal myocardium."( Sodium-calcium exchange in neonatal myocardium: reversible inhibition by halothane.
Baum, VC; Wetzel, GT, 1994
)
0.98
"Halothane has been shown to reduce responsiveness through both of these mechanisms."( Effects of halothane, propofol, and thiopental on peripheral airway reactivity.
Lindeman, KS; Mehr, EH, 1993
)
1.4
"Halothane has been reported to inhibit endothelium-dependent relaxation in a variety of vessels. "( Effects of halothane on EDRF/cGMP-mediated vascular smooth muscle relaxations.
Bina, S; Freas, W; Hart, JL; Jing, M; Muldoon, SM; Van Dyke, RA, 1993
)
2.12
"Halothane has become the preferred anesthetic agent during fetal surgery because it can be administered via maternal inhalation and it improves surgical exposure by relaxing the uterus. "( Halothane as an anesthetic for fetal surgery.
Assad, RS; Hanley, FL; Sabik, JF, 1993
)
3.17
"Halothane has been reported to affect the integrity of intracellular Ca2+ stores in a number of tissues including vascular smooth muscle. "( Dual actions of halothane on intracellular calcium stores of vascular smooth muscle.
Akata, T; Boyle, W, 1996
)
2.08
"Halothane has two distinct actions on the intracellular Ca2+ stores of vascular smooth muscle, a Ca2+ releasing action and a stimulating action on Ca2+ uptake. "( Dual actions of halothane on intracellular calcium stores of vascular smooth muscle.
Akata, T; Boyle, W, 1996
)
2.08
"Halothane has a direct action on vascular smooth muscle cells and causes relaxation of these cells, yet neither the mechanism nor the site of its action is completely understood. "( The effects of halothane on arginine-vasopressin-induced Ca2+ mobilization from the intracellular stores and the receptor-mediated Ca2+ entry from the extracellular space in single cultured smooth muscle cells of rat aorta.
Fujihara, H; Fujiwara, N; Fukuda, S; Shimoji, K, 1996
)
2.09
"Halothane has an effect at the endothelial receptor level, but not any distal steps in the NO-cGMP pathway."( Isoflurane and halothane attenuate endothelium-dependent vasodilation in rat coronary microvessels.
Dai, HB; Darvish, A; Lowenstein, E; Park, KW; Sellke, FW, 1997
)
1.37
"Halothane thus has two distinct actions on PKC in synaptosomes: activation of endogenous PKC activity and potentiation of activation-induced cPKC translocation and down-regulation."( Effect of halothane on conventional protein kinase C translocation and down-regulation in rat cerebrocortical synaptosomes.
Adamo, AI; Hemmings, HC, 1997
)
1.42
"Halothane has the weakest potentiating effect on neuromuscular blocking drugs and previous studies of the interaction between halothane and mivacurium have been contradictory."( The effect of halothane on mivacurium infusion requirements in adult surgical patients.
Kansanaho, M; Olkkola, KT, 1997
)
1.38
"Halothane has been shown to inhibit the action of NO on blood vessels."( Halothane attenuates nitric oxide relaxation of rat aortas by competition for the nitric oxide receptor site on soluble guanylyl cyclase.
Bina, S; Hart, JL; Jing, M; Ling, GS; Muldoon, SM, 1998
)
2.46
"Once halothane hepatitis has developed, there are no specific treatments and liver replacement may be required."( Halothane hepatitis.
Neuberger, J, 1998
)
2.2
"Halothane has been shown to be a powerful myocardial protectant during normothermic cardioplegic arrest and subsequent reperfusion. "( Postcardioplegic myocardial recovery: effects of halothane, nifedipine, HOE 694, and quinacrine.
Genade, S; Lochner, A; Theron, S; Trollip, G; Tromp, E, 1998
)
2
"Halothane has been shown to inhibit platelet aggregation and may, therefore, prevent intraoperative platelet activation. "( Volatile anaesthetics induce changes in the expression of P-selectin and glycoprotein Ib on the surface of platelets in vitro.
Fröhlich, D; Hansen, E; Rothe, G; Schmitz, G, 1998
)
1.74
"Halothane has been shown to inhibit m1 muscarinic signalling."( Volatile anaesthetics have differential effects on recombinant m1 and m3 muscarinic acetylcholine receptor function.
Chan, CK; Durieux, ME; Hönemann, CW; Kamatchi, GL; Nietgen, GW, 1998
)
1.02
"Halothane has many effects on the resting membrane potential (V(m)) of excitable cells and exerts numerous effects on skeletal muscle one of which is the enhancement of Ca(2+) release by the sarcoplasmic reticulum (SR) resulting in a sustained contracture. "( Effects of halothane on the membrane potential in skeletal muscle of the frog.
Descorps-Declère, A; Frizelle, HP; Mazoit, JX; Sauviat, MP, 2000
)
2.14
"Halothane screening has been used in the swine industry to identify animals susceptible to stress and prone to developing pale, soft, exudative (PSE) meat. "( The use of halothane gas to identify turkeys prone to developing pale, exudative meat when transported before slaughter.
Matthews, NS; Owens, CM; Sam, AR, 2000
)
2.14
"1. Halothane has been shown to affect several membrane currents in cardiac tissue including the L-type calcium current (I(Ca)), sodium current and a variety of potassium currents. "( Effects of halothane on the transient outward K(+) current in rat ventricular myocytes.
Boyett, MR; Davies, LA; Harrison, SM; Hopkins, PM, 2000
)
1.32
"Halothane (H) has been shown to reduce conductance of connexin-43 hemichannels and to protect the heart against ischemic injury."( Activation of connexin-43 hemichannels can elevate [Ca(2+)]i and [Na(+)]i in rabbit ventricular myocytes during metabolic inhibition.
Barry, WH; Li, F; Su, Z; Sugishita, K; Ueda, I, 2001
)
1.03
"Halothane has been found to undergo a reductive defluorination. "( Anaerobic release of fluoride from halothane. Relationship to the binding of halothane metabolites to hepatic cellular constituents.
Gandolf, AJ; Van Dyke, RA,
)
1.85
"Halothane has dual effects on lipolysis of human adipose tissue: at low tissue concentrations a stimulatory effect is found, while at higher tissue concentrations lipolysis is inhibited. "( Studies of the dual effects of halothane on the lipolysis of human fat cells.
Bennis, J; Smith, U, 1976
)
1.98
"Halothane hepatitis has been a matter of continuing controversy, but now it seems to be generally accepted as a clinical entity."( Halothane hepatitis.
Ranek, L, 1978
)
2.42
"Halothane has been shown to undergo an oxidative dechlorination and a reductive defluorination."( Dechloriation mechanisms of chlorinated olefins.
Van Dyke, RA, 1977
)
0.98
"Halothane has been shown to depress neurotransmission by L-glutamate and N-methyl-D-aspartate."( Nitric oxide synthase inhibitor dose-dependently and reversibly reduces the threshold for halothane anesthesia. A role for nitric oxide in mediating consciousness?
DiFazio, CA; Johns, RA; Moscicki, JC, 1992
)
1.23
"Halothane has no effect on scotopic b-wave stimulus/response parameters, including amplitude, sensitivity, and implicit time. "( Effects of halothane on children's electroretinograms.
Fulton, AB; Gudas, VM; Hansen, RM; Koka, B; Wongpichedchai, S, 1992
)
2.12
"Halothane previously has been shown to attenuate EDRF-induced vasodilation elicited by the receptor-mediated vasodilators acetylcholine and bradykinin and to alter muscarinic receptor activity."( Halothane, enflurane, and isoflurane attenuate both receptor- and non-receptor-mediated EDRF production in rat thoracic aorta.
Johns, RA; Proctor, GJ; Uggeri, MJ, 1992
)
2.45
"Halothane has either proarrhythmic or antiarrhythmic effects in a variety of clinical circumstances. "( The effects of halothane on ventricular tachycardia in intact dogs.
Gallagher, JD; McClernan, CA, 1991
)
2.08
"Halothane exposure has proved to be quite useful as an experimental tool in the study of neural and behavioral recovery after brain lesions."( Neurobehavioral toxicology of halothane in rats.
Bowman, RE; Levin, ED; Uemura, E,
)
1.14
"Halothane has been used as internal standard."( Porous-layer open-tubular gas chromatography in combination with an ion trap detector to assess volatile metabolites in human breath.
Ghoos, Y; Hiele, M; Rutgeerts, P; Vantrappen, G, 1989
)
1
"When halothane hepatitis has occurred, treatment is purely supportive with the possibility of transplantation for those in grade IV encephalopathy."( Halothane hepatitis.
Neuberger, J; Williams, R, 1988
)
2.17
"Halothane has been shown to produce significant changes in heart rate and strength of contraction. "( Prolongation of the action potential and reduction of the delayed outward K+ current by halothane in single frog atrial cells.
Hirota, K; Ito, Y; Momose, Y; Nakanishi, S; Takeda, R, 1986
)
1.94
"Halothane has enzyme-inducing properties after a single exposure in children, while a single dose of ketamine does not."( Increased hepatic microsomal activity after halothane anaesthesia in children.
Clemmensen, A; Hjortsø, E; Loft, S; St Haxholdt, O, 1986
)
1.25

Actions

Halothane and enflurane produce an initial liberation of Ca++ from internal stores, while isoflurane does not. Halothane appears to inhibit BBB glucose transport by competing for the glucose carrier.

ExcerptReferenceRelevance
"Halothane appears to increase the level of radiation-induced DNA damage, while sevoflurane and isoflurane exhibited a protective effect. "( DNA damage assessment in peripheral blood of Swiss albino mice after combined exposure to volatile anesthetics and 1 or 2 Gy radiotherapy in vivo.
Benković, V; Borojević, N; Horvat Knežević, A; Milić, M; Šikić, D, 2021
)
2.06
"Halothane depressed the increase in intracellular calcium with hypoxia more than did sevoflurane (P=0.036). "( Differential effects of halothane and sevoflurane on hypoxia-induced intracellular calcium transients of neonatal rat carotid body type I cells.
Buckler, KJ; Pandit, JJ, 2009
)
2.1
"The halothane-induced increase in [Ca(2+)](i) differed significantly between the three diagnostic groups. "( Phenotyping malignant hyperthermia susceptibility by measuring halothane-induced changes in myoplasmic calcium concentration in cultured human skeletal muscle cells.
Censier, K; Girard, T; Mueller, CR; Treves, S; Urwyler, A; Zorzato, F, 2002
)
1.11
"Halothane induced a lower negative inotropic effect in senescent rats (1.5 vol%, AF: 53 +/- 14% vs."( Myocardial effects of halothane and isoflurane in senescent rats.
Besse, S; Coriat, P; Riou, B; Rozenberg, S; Vivien, B, 2002
)
1.35
"Halothane was able to increase [Ca2+]i in those neurons in a dose-dependent manner and independent of extracellular calcium."( Effect of halothane on the release of [Ca2+]i in dorsal root ganglion neurons.
Gomes, DA; Gomez, MV; Gomez, RS; Guatimosim, C; Leite, MF; Prado, MA; Romano-Silva, MA; Vieira, LB, 2004
)
1.45
"Halothane and propofol enhance the activity of the gamma-aminobutyric acid (GABA) system, which is one of the most important systems in the mechanism of anesthesia. "( Halothane and propofol modulation of gamma-aminobutyric acidA receptor single-channel currents.
Kitamura, A; Marszalec, W; Narahashi, T; Ogawa, R; Sato, R; Yeh, JZ, 2004
)
3.21
"Halothane as a cause of hepatitis is rare and may be overlooked when evaluating a patient with sudden onset jaundice. "( Halothane induced hepatitis: case report.
Otedo, AE, 2004
)
3.21
"Halothane is known to cause acute and chronic hepatotoxicity because of its biotransformation into trifluoroacytelated polypeptides."( In vivo interaction of pulmonary intravascular macrophages with activated platelets in microvessels of equine lung after multiple exposures to halothane, isoflurane, and thiamylal: a comparative ultrastructural and cytochemical study.
Atwal, OS; McDonell, W, 2005
)
1.25
"Halothane may inhibit the plasma membrane Ca2+-ATPase of vascular smooth muscle cells."( Multiple actions of halothane on contractile response to noradrenaline in isolated mesenteric resistance arteries.
Akata, T; Izumi, K; Takahashi, S; Yoshino, J, 2005
)
1.37
"Halothane does not inhibit the biochemical coupling between the beta2 receptor and Galphas and hence does not affect the inhibition of calcium sensitivity induced by isoproterenol. "( Halothane does not inhibit the functional coupling between the beta2-adrenergic receptor and the Galphas heterotrimeric G protein.
Hayashi, M; Jones, KA; Nakayama, T; Penheiter, AR; Penheiter, SG; Warner, DO, 2006
)
3.22
"Halothane induced an increase on the release of [(3)H]DA that was dependent on incubation time and anesthetic concentration (0.012, 0.024, 0.048, 0.072 and 0.096 mM)."( Halothane increases non-vesicular [(3)H]dopamine release from brain cortical slices.
Diniz, PH; Gomez, MV; Gomez, RS; Guatimosim, C; Silva, JH, 2007
)
2.5
"Halothane induced an increase on the release of [3H]5-HT that was dependent on incubation time and anesthetic concentration (0.006, 0.012, 0.024, 0.036, 0.048 and 0.072 mM)."( Halothane induces vesicular and carrier-mediated release of [3H]serotonin from rat brain cortical slices.
Gomez, MV; Gomez, RS; Guatimosim, C; Silva, JH, 2008
)
2.51
"Halothane may increase its own toxicity by increasing the activity of NADPH-cytochrome-c-reductase in liver."( Drug metabolizing enzymes in the rat after inhalation of halothane and enflurane. Different pattern of response in liver, kidney and lung and possible implications for toxicity.
Dale, O; Nielsen, K; Nilsen, OG; Westgaard, G, 1983
)
1.23
"Halothane produced lower blood pressures, fewer ECG changes, and lower heart rates than those seen in conscious or fentanyl anesthetized rats."( Effects of halothane anesthesia compared with fentanyl anesthesia and no anesthesia during coronary ligation in rats.
Augereau, P; MacLeod, BA; Walker, MJ, 1983
)
1.38
"Halothane was found to produce a significant, dose-dependent decrease in EES from 10.6 +/- 0.6 control to 6.7 +/- 0.4 at 1% halothane and 4.2 +/- 0.5 at 2% halothane (p less than 0.05, control versus both 1% and 2% halothane)."( The mechanism of halothane-induced myocardial depression. Altered diastolic mechanics versus impaired contractility.
Christian, CC; Fagraeus, L; Jones, RN; Pasque, MK; Pellom, GL; Peyton, RB; Spray, TL; Van Trigt, P; Wechsler, AS, 1983
)
1.33
"Halothane is known to inhibit the ventilatory responses to hypoxia and hypercapnia. "( Halothane depresses the response of carotid body chemoreceptors to hypoxia and hypercapnia in the cat.
Davies, RO; Edwards, MW; Lahiri, S, 1982
)
3.15
"Halothane and enflurane cause a dose-dependent decrease of the contractile properties of the cat papillary muscle."( [The influence of adrenaline on the effects of halothane and enflurane on the myocardium. Papillary muscle of the cat (author's transl)].
Hohle, R; Siepmann, HP, 1980
)
1.24
"A 3% halothane-induced increase in [Ca2+]cyt was observed in the Ca(2+)-free solution even when the muscle strip was pretreated with a 10(-6)-M dose of ryanodine and a 20-mM dose of caffeine, whereas it was abolished completely after the muscle strip was pretreated with ryanodine, caffeine, and 100 nM norepinephrine."( Effects of halothane and isoflurane on cytosolic calcium ion concentrations and contraction in the vascular smooth muscle of the rat aorta.
Fujita, S; Namba, H; Namiki, A; Notsuki, E; Tsuchida, H; Yamakage, M, 1993
)
1.13
"Halothane did not produce cell damage except for the longest exposure durations (8 and 12 h) at 2% vapor concentration."( Effects of halothane on surfactant biosynthesis by rat alveolar type II cells in primary culture.
Aubier, M; Bastin, J; Crestani, B; Desmonts, JM; Dureuil, B; Molliex, S; Rolland, C, 1994
)
1.4
"Halothane, at lower concentrations, appeared to induce early morphological alterations of the plasma membrane, while higher concentrations damaged the organella."( Halothane-induced cytotoxicity in isolated rat hepatocytes: an electron microscopic study.
Amakata, Y; Kawahara, M; Kinugawa, H; Maeda, T,
)
2.3
"This halothane-induced increase was enhanced by 14% O(2), but hypoxia alone had no significant effect."( Demonstration of halothane-induced hepatic lipid peroxidation in rats by quantification of F2-isoprostanes.
Awad, JA; Franks, JJ; Horn, JL; Roberts, LJ, 1996
)
1.09
"Halothane inhibited the increase in inositol 1,4,5-triphosphate induced by thrombin."( Direct inhibitory mechanisms of halothane on human platelet aggregation.
Kohro, S; Yamakage, M, 1996
)
1.3
"Halothane can inhibit the nitric oxide-cyclic GMP mechanism only when Ca2+ release is greatly involved in the activation of constitutive nitric oxide synthase."( A beta-adrenoceptor agonist evokes a nitric oxide-cGMP relaxation mechanism modulated by adenylyl cyclase in rat aorta. Halothane does not inhibit this mechanism.
Hatano, Y; Iranami, H; Maeda, H; Mizumoto, K; Tsukiyama, Y, 1996
)
1.22
"Halothane appeared to suppress both TXA2 formation and binding to its receptors."( Sevoflurane inhibits human platelet aggregation and thromboxane A2 formation, possibly by suppression of cyclooxygenase activity.
Hatano, Y; Hirakata, H; Mori, K; Nakamura, K; Narumiya, S; Sai, S; Toda, H; Urabe, N; Ushikubi, F, 1996
)
1.02
"Halothane 2% did not increase the mortality in traumatized mice."( Influence of anesthesia protocol in experimental traumatic brain injury.
Mesenge, H; Plotkine, M; Stutzmann, AM; Tecoult, E; Wahl, F, 2000
)
1.03
"Halothane failed to increase the release of ACh in striatal slices after lesion by 6-OH-dopamine."( Halothane enhances acetylcholine release by decreasing dopaminergic activity in rat striatal slices.
Adachi, YU; Higuchi, H; Satoh, T; Watanabe, K; Zsilla, G, 2002
)
2.48
"The halothane B/G did not increase significantly at the inception of CPB but decreased from a mean 2.7 to 1.6 as the patients were rewarmed."( Crystalloid hemodilution, hypothermia, and halothane blood solubility during cardiopulmonary bypass.
Feingold, A,
)
0.87
"Halothane appears to inhibit BBB glucose transport by competing for the glucose carrier and by altering the affinity of the carrier for glucose, perhaps by altering the environment of the carrier or the carrier itself."( Glucose transport across the rat blood-brain barrier during anesthesia.
MacMurdo, D; Nemoto, EM; Stezoski, SW, 1978
)
0.98
"Halothane is said to inhibit transport of the L-dopa precursor L-tyrosine from plasma to brain tissue."( [Effect of halothane on catecholamine metabolism in the brain stem of rats].
Schulte, J, 1976
)
1.37
"Halothane may cause a conformational change of membrane proteins, particularly of the nicotinic receptor (and at higher concentrations of GABA and 5-hydroxytryptamine receptors); thus, stimulation may be prevented by an inhibition of agonist-receptor interaction."( Inhibition of catecholamine release from the adrenal medulla by halothane. Site and mechanism of action.
Dorn, W; Göthert, M; Loewenstein, I, 1976
)
1.22
"The halothane diagrams increase critically at high doses, whereas the courves for CCl(4) and CHCl(3) rise continuously."( [Swelling and loss of potassium in perfused livers following the influence of the vapours of carbon tetrachloride, chloroform and halothane on the perfusion medium (author's transl)].
Frimmer, M; Lutz, F, 1975
)
0.94
"Halothane causes an increase in the electrode signal which is proportional to its concentration."( Errors in oxygen tension measurements caused by halothane.
Dent, JG; Netter, KJ, 1976
)
1.23
"Halothane may enhance the reduction in the myofibrillar response to activator Ca2+ when the muscle fiber length is shortened."( Contribution of the known subcellular effects of anesthetics to their negative inotropic effect in intact myocardium.
Komai, H; Rusy, BF, 1991
)
1
"Halothane was chosen because its actions in the microcirculation have been determined previously."( Halothane attenuates small arteriole vasodilation to serotonin (5-HT) in skeletal muscle.
Alsip, NL; Asher, EF; Harris, PD; Zhang, PY, 1991
)
2.45
"Halothane and enflurane produce an initial liberation of Ca++ from internal stores, while isoflurane does not."( [Mechanisms of action of halogenated anesthetics on isolated cardiac muscle].
Murat, I, 1990
)
1
"Halothane was found to increase the train-of-four fade during the recovery phase compared with control."( Influence of halothane on the train-of-four fade after atracurium in children.
Woloszczuk-Gebicka, B, 1990
)
1.37
"A halothane-induced increase in time-to-peak contraction was also observed at membrane potentials in the range of the action potential plateau (+20 and +40 mV)."( Influence of halothane on contraction at positive membrane potentials in single cells isolated from guinea-pig ventricular muscle.
Terrar, DA; Victory, JG, 1989
)
1.2
"The halothane-induced increase in [Ca2+]i required extracellular calcium ions."( Anaesthetic-induced increase in ionised calcium in blood mononuclear cells from malignant hyperthermia patients.
Britt, BA; Elliott, ME; Frodis, W; Klip, A; Pegg, W; Scott, E, 1987
)
0.75
"Halothane caused an increase in vMCA by more than one third of the preanesthetic value (from 54.4 +/- 12.2."( [Transcranial Doppler sonography: halothane increases average blood flow velocity in the middle cerebral artery].
Beverungen, M; Cunitz, G; Schregel, W, 1988
)
1.28
"The halothane-mediated increase in cytoplasmic ionized Ca2+ required extracellular Ca2+."( Selective increase in cytoplasmic calcium by anesthetic in lymphocytes from malignant hyperthermia-susceptible pigs.
Britt, BA; Elliott, ME; Klip, A; Ramlal, T; Walker, D, 1987
)
0.75
"Halothane produce an increase in latency a decrease in amplitude and at higher concentrations even abolished the later waves of middle latency auditory evoked responses."( Brainstem and middle latency auditory evoked responses in rabbits with halothane anaesthesia.
Ciges, M; de Carlos, R; de la Cruz, T; Martinez, F; Sainz, M,
)
1.09
"Halothane is thought to cause hepatitis after multiple exposures in certain susceptible patients. "( Jaundice after multiple halothane anaesthetics administered during the treatment of carcinoma of the uterus.
Davis, P; Holdsworth, CD, 1973
)
2

Treatment

Halothane treatment provided no cardioprotection and seemed to inhibit protection by anoxic preconditioning. Halothane significantly diminished carbachol-induced increases in [Ca2+]i by 77% and muscle tension by 83% in a dose-dependent manner.

ExcerptReferenceRelevance
"In halothane-treated females, plasma concentration of tumor necrosis factor-alpha was greater than in males, and neutrophils were recruited to liver more rapidly and to a greater extent."( A mouse model of severe halothane hepatitis based on human risk factors.
Dugan, CM; Ganey, PE; MacDonald, AE; Roth, RA, 2010
)
1.18
"Halothane-treated PAM exposed to air recovered to the extent that their luminol CL responses were significantly greater than control (no halothane) experiments."( Halothane inhibits the microbicidal oxidative activity of pulmonary alveolar macrophages.
Welch, WD, 1983
)
2.43
"Late halothane treatment was ineffective when given as early as 10 minutes postinjury while both the electrophysiological and hemodynamic effects of halothane vs."( Halothane anesthesia is neuroprotective in experimental spinal cord injury: early hemodynamic mechanisms of action.
Agresta, CA; Kelly, G; Lee, WA; Mendez, AA; Sabato, S; Salzman, SK, 1993
)
2.18
"Halothane-treated females had increased amounts of specific antibody secreting B cells, with liver studies showing evidence of microscopic fatty changes and decreased lipid peroxidation."( Effects of halothane reexposure in female mice and their offspring.
Amerio, N; Barragán, J; Comba, JO; Elena, GA; Piaggio, E; Puig, NR,
)
1.24
"Halothane treatment provided no cardioprotection and seemed to inhibit protection by anoxic preconditioning."( Isoflurane, but not halothane, induces protection of human myocardium via adenosine A1 receptors and adenosine triphosphate-sensitive potassium channels.
Christensen, JD; Lynch, C; Roscoe, AK, 2000
)
1.35
"Halothane-pretreated animals were subjected to MCAO 24 hours after AP."( Tolerance against ischemic neuronal injury can be induced by volatile anesthetics and is inducible NO synthase dependent.
Dirnagl, U; Fütterer, C; Isaev, NK; Kapinya, KJ; Löwl, D; Maurer, M; Waschke, KF, 2002
)
1.04
"Halothane- and air-treated lymphocytes, prior to PHA addition, had the same content of cyclic AMP."( Halothane action on lymphocytes does not involve cyclic AMP.
Bruce, DL, 1976
)
2.42
"Halothane treatment of resting tentacles also gave indications of the presence of differentially stable intermicrotubule-bridges."( Microtubules and associated microfilaments in the tentacles of the suctorian Heliophrya erhardi Matthes.
Hauser, M; Van Eys, H, 1976
)
0.98
"The halothane-treated rats entered significantly fewer arms before reentering an arm (entries-to-repeat)."( Behavioral effects of chronic exposure to low concentrations of halothane during development in rats.
Bowman, RE; Levin, ED, 1986
)
0.99
"Halothane-treatment of the brain increased both the T1 and T2 times considerably, as expected from the disruption of the phospholipid bilayer in a membrane."( Characterization of the broad resonance in 31P NMR spectra of excised rat brain.
Arús, C; Bárány, M; Chang, YC, 1985
)
0.99
"Treatment with halothane resulted in the formation of a preponderance of slowly sedimenting virus nucleocapsid particles which contained less than full-length ribonucleic acids after anesthetic removal."( Inhibiting effects of enflurane and isoflurane anesthesia on measles virus replication: comparison with halothane.
Bedows, E; Knight, PR; Nahrwold, ML, 1981
)
0.82
"Treatment with halothane during the early reperfusion period after myocardial ischaemia protected the myocardium against infarction in vivo, independent of the haemodynamic effect of halothane."( Halothane reduces reperfusion injury after regional ischaemia in the rabbit heart in vivo.
Barthel, H; Obal, D; Preckel, B; Schlack, W; Thämer, V, 1997
)
2.08
"Treatment with halothane (2.3%) or isoflurane (2.3% and 3.5%) attenuated the relaxant response to TES (P < 0.05)."( Halothane and isoflurane attenuate the relaxant response to nonadrenergic and noncholinergic nerve stimulation of isolated canine cerebral arteries.
Hatano, Y; Iranami, H; Ogawa, K; Tajima, T; Yamamoto, M, 1998
)
2.08
"Pretreatment with halothane significantly diminished carbachol-induced increases in [Ca2+]i by 77% and muscle tension by 83% in a dose-dependent manner. "( Role of intracellular Ca2+ stores in the inhibitory effect of halothane on airway smooth muscle contraction.
Kohro, S; Matsuzaki, T; Namiki, A; Tsuchida, H; Yamakage, M, 1998
)
0.87
"Treatment with halothane was discontinued after 120 min inhalation."( [The changes in total and free catecholamine level in plasma in a patient with status asthmaticus].
Kaneda, T; Morisaki, H; Takino, Y, 1991
)
0.62

Toxicity

The incidence of agitation attributable to sevoflurane was almost threefold greater than that attributable to halothane. Turpentine was most toxic followed by Halothane and chloroform, which caused similar levels of cell injury. Catechin suppresses lipid peroxidation and increases enzyme activity, therefore it seems to be capable of protecting liver parenchyma against the direct toxic effect of halothsane.

ExcerptReferenceRelevance
"A review of the anesthesia literature outlines safe limits for use of epinephrine with halothane anesthesia and adequate ventilation."( Safe use of epinephrine with halothane anesthesia.
Lowry, LD, 1977
)
0.77
" The occasionally observed liver and kidney injuries indicate a potential formation of toxic metabolites."( [The biotransformation of inhalation anaesthetics and its relevance to clinical side effects (author's transl)].
Rietbrock, I, 1975
)
0.25
" Also, S-(2-bromo-2-chloro-1,1-difluoroethyl)-DL-alpha-methylcysteine, which can not be metabolized by beta-lyase, was not toxic to LLC-PK1 cells."( Nephrotoxicity of the glutathione and cysteine conjugates of 2-bromo-2-chloro-1,1-difluoroethene.
Anders, MW; Baggs, RB; Finkelstein, MB, 1992
)
0.28
" In six MH(-) patients with previous masseter muscle rigidity, no adverse reactions occurred in response to volatile anesthetic agents."( Safety of general anesthesia in patients previously tested negative for malignant hyperthermia susceptibility.
Allen, GC; Fletcher, JE; Rosenberg, H, 1990
)
0.28
"The influence of age and volatile anesthetic agents on plasma concentrations and toxic effects of bupivacaine were studied in 2-day-old, 2-week-old, and 2-month-old pigs."( Bupivacaine toxicity in young pigs is age-dependent and is affected by volatile anesthetics.
Badgwell, JM; Heavner, JE; Kytta, J, 1990
)
0.28
" A toxic effect of isoflurane was not observed under identical experimental conditions."( Comparative toxicity of halothane, isoflurane, hypoxia, and phenobarbital induction in monolayer cultures of rat hepatocytes.
Costa, AK; Heffel, DF; Schieble, TM; Trudell, JR, 1988
)
0.58
"The volatile inhalation anaesthetics have been implicated in a variety of adverse viscerotoxic reactions."( Adverse effects of volatile anaesthetics.
Brown, BR; Gandolfi, AJ, 1987
)
0.27
" We tested whether toxic products were produced by the passage of sevoflurane through soda lime, and a comparison was made of the toxicity of sevoflurane passed through soda lime with the toxicity of other potent volatile anesthetics in current clinical use."( Toxicity of sevoflurane in rats.
Eger, EI; Ferrell, LD; Johnson, BH; Steffey, EP; Strum, DP, 1987
)
0.27
" Furthermore, (+)-catechin seems capable of protecting against the direct toxic effect of halothane metabolites resulting from the reductive pathways."( Halothane hepatotoxicity in glutathione depleted rats.
Sellin, D; Siegers, CP; Wilhelm, KP; Younes, M, 1987
)
1.94
"The physical stability and low blood solubility of the new inhaled anesthetic, I-653, imply that this agent produces limited or no toxic effects."( Studies of the toxicity of I-653, halothane, and isoflurane in enzyme-induced, hypoxic rats.
Eger, EI; Ferrell, LD; Johnson, BH; Strum, DP, 1987
)
0.55
" The LD50 (30 day) for cyclophosphamide without halothane was 251 mg/kg; with 2 h subsequent exposure to halothane it was 152 mg/kg; and with 20 h subsequent exposure to halothane it was 158 mg/kg."( Increased toxicity of the antitumor drug cyclophosphamide in mice in the presence of the volatile anesthetic agent halothane.
Kooistra, KL; Powis, G; Rosenow, S; Van Dyke, RA, 1986
)
0.74
" In 95% O2 halothane is more toxic than enflurane when RHS are exposed to 5-20 microliters of these anesthetics."( Toxicity and biotransformation of volatile halogenated anesthetics in rat hepatocyte suspensions.
Brendel, K; Brooks, SD; DiRenzo, AB; Gandolfi, AJ, 1985
)
0.66
" In this model, liver injury is caused by toxic intermediates formed during metabolism of halothane by a reductive pathway."( Effects of cimetidine and ranitidine on halothane metabolism and hepatotoxicity in an animal model.
Cousins, MJ; Hall, PD; Jenner, MA; Plummer, JL; Wanwimolruk, S,
)
0.62
"During the decade 1968-1978 the Danish Board of Adverse Reactions to Drugs received 572 (6% of the total number) reports on hepatotoxicity."( Drug-induced liver disease in Denmark. An analysis of 572 cases of hepatotoxicity reported to the Danish Board of Adverse Reactions to Drugs.
Andreasen, PB; Døssing, M, 1982
)
0.26
"The otherwise safe and useful anaesthetic halothane has been suspected of producing the occasional complication of hepatic necrosis, ascribed either to a drug allergy or to biotransformation to reactive intermediates."( Halogenated analgesics and hepatotoxicity.
Brown, BR, 1981
)
0.53
"Subcutaneous administration of the N-methyl-D-aspartic acid (NMDA) antagonist, MK-801, to adult rats causes a toxic vacuole reaction in neurons of the posterior cingulate cortex which is readily detected in histological sections 4 h following MK-801 administration."( Halothane prevents MK-801 neurotoxicity in the rat cingulate cortex.
Fukamauchi, F; Ishimaru, M; Olney, JW, 1995
)
1.73
" None of the animals given halothane had seizures, but they did exhibit the other three toxic endpoints."( Bupivacaine toxicity in lightly anesthetized pigs with respiratory imbalances plus or minus halothane.
Badgwell, JM; Dryden, CF; Flinders, C; Heavner, JE,
)
0.65
" Turpentine was most toxic followed by halothane and chloroform, which caused similar levels of cell injury."( Cytotoxic effects of gutta-percha solvents.
Barbosa, SV; Burkard, DH; Spångberg, LS, 1994
)
0.56
" Halothane had no toxic effect, even when glutathione was depleted before the onset of hypoxia."( Effect of halothane on hypoxic toxicity and glutathione status in cultured rat hepatocytes.
Johnson, ME; Sill, JC; Uhl, CB; Van Dyke, RA, 1993
)
1.6
" The incidence of adverse events was similar for both anesthetics."( Induction, recovery, and safety characteristics of sevoflurane in children undergoing ambulatory surgery. A comparison with halothane.
Carpenter, R; Davis, PJ; Haberkern, CM; Hannallah, R; Lerman, J; Motoyama, E; Orr, RJ; Rabb, M; Welborn, LG, 1996
)
0.5
"Carbon dioxide absorbents degrade both halothane and sevoflurane to toxic unsaturated compounds (CF2=CBrCl and CH2F-O-C[=CF2][CF3] [i."( Quantitative differences in the production and toxicity of CF2=BrCl versus CH2F-O-C(=CF2)(CF3) (compound A): the safety of halothane does not indicate the safety of sevoflurane.
Eger, EI; Gong, D; Ionescu, P; Kerschmann, RL; Laster, MJ; Weiskopf, RB, 1997
)
0.77
" This was followed by toxic effects on peritoneal organs and surfaces, except for sevoflurane, which did not produce any lesions."( Fluorinated anesthetics differ in toxic effects on peritoneum and subjacent tissues.
Levine, S; Saltzman, A,
)
0.13
" Drug-induced hepatitis is generally divided into two categories: acute hepatitis in which the drug or a metabolite destroys a vital target in the cell; immunoallergic hepatitis in which the drug triggers an adverse immune response directed against the liver."( Drug-induced immunotoxicity.
Beaune, PH; Bonierbale, E; Dansette, PM; Mansuy, D; Minoletti, C; Pessayre, D,
)
0.13
" Catechin suppresses lipid peroxidation and increases enzyme activity, therefore it seems to be capable of protecting liver parenchyma against the direct toxic effect of halothane."( Hepatobiliary scintigraphy for evaluating the hepatotoxic effect of halothane and the protective effect of catechin in comparison with histo-chemical analysis of liver tissue.
Ciftçi, S; Karamanlioğlu, B; Salihoğlu, YS; Temiz, E; Yüksel, M, 2002
)
0.74
"High concentrations of organic solvents have adverse effects on the health of professional workers."( [Solvents for the removal of gutta-percha from root canals. 2. Side effects of chloroform, halothane and xylene].
Moorer, WR; Schuur, AH; Wesselink, PR, 2004
)
0.54
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
"General anesthesia produced physiological perturbations, exacerbated local anesthetic-induced cardiovascular depression, and changed the pharmacokinetics of toxic doses of local anesthetics."( The effects of general anesthesia on the central nervous and cardiovascular system toxicity of local anesthetics.
Copeland, SE; Gu, XQ; Ladd, LA; Mather, LE, 2008
)
0.35
"The study concludes that zinc has the potential to alleviate the toxic effects of halothane in rat liver."( Protective role of zinc pretreatment in hepatotoxicity induced by halothane.
Celik, JB; Esen, H; Otelcioglu, S; Toy, H; Unsal, C, 2008
)
0.81
"Given limited information regarding the pathophysiology underlying aciclovir-associated, clinically observed cardiovascular adverse events including chest pain, tachycardia, bradycardia, palpitation, arrhythmia, hypertension and hypotension, we investigated its electropharmacological effects using the halothane-anesthetized beagle dogs."( Electropharmacological Characterization of Aciclovir in the Halothane-Anesthetized Dogs: A Proposal of Evaluation Method for Cardiovascular Safety Pharmacology of Anti-virus Drugs.
Chiba, K; Goto, A; Hagiwara-Nagasawa, M; Izumi-Nakaseko, H; Kambayashi, R; Kondo, Y; Matsumoto, A; Nunoi, Y; Sugiyama, A, 2020
)
0.98
" To clarify how lamotrigine induces those cardiovascular adverse events, we simultaneously assessed its cardiohemodynamic and electrophysiological effects using the halothane-anesthetized dogs (n = 4)."( Reverse translational analysis of clinically reported, lamotrigine-induced cardiovascular adverse events using the halothane-anesthetized dogs.
Goto, A; Hagiwara-Nagasawa, M; Izumi-Nakaseko, H; Kambayashi, R; Kawai, S; Matsumoto, A; Nunoi, Y; Sugiyama, A; Takei, Y, 2021
)
1.03
" Our aim was to investigate the occurrence of serious adverse effects and the adherence to oral dantrolene therapy."( Oral Dantrolene for Myopathic Symptoms in Malignant Hyperthermia-Susceptible Patients: A 25-Year Retrospective Cohort Study of Adverse Effects and Tolerability.
Ibarra Moreno, CA; Jungbluth, H; Kraeva, N; Riazi, S; Voermans, NC; Zvaritch, E, 2023
)
0.91
" There were no serious adverse effects reported."( Oral Dantrolene for Myopathic Symptoms in Malignant Hyperthermia-Susceptible Patients: A 25-Year Retrospective Cohort Study of Adverse Effects and Tolerability.
Ibarra Moreno, CA; Jungbluth, H; Kraeva, N; Riazi, S; Voermans, NC; Zvaritch, E, 2023
)
0.91
"We found that oral dantrolene produced no serious adverse effects within the reported dose range, and was well tolerated by most MH-susceptible patients presenting myopathic symptoms."( Oral Dantrolene for Myopathic Symptoms in Malignant Hyperthermia-Susceptible Patients: A 25-Year Retrospective Cohort Study of Adverse Effects and Tolerability.
Ibarra Moreno, CA; Jungbluth, H; Kraeva, N; Riazi, S; Voermans, NC; Zvaritch, E, 2023
)
0.91

Pharmacokinetics

The transtrans and cis-trans isomers of mivacurium have a long half-life and slow clearance in healthy dogs anesthetized with halothane. The apparent elimination half- life was longer and the total voluem of distribution at steady state larger during Halothane anesthesia.

ExcerptReferenceRelevance
" The apparent elimination half-life was longer and the total voluem of distribution at steady state larger during halothane anesthesia."( Effect of different anesthetics on the pharmacokinetics and pharmacodynamics of pancuronium in the cat.
Agoston, S; Booij, LH; Crul, JF; Miller, RD; van der Pol, F, 1979
)
0.47
" All other pharmacodynamic parameters were similar."( A comparison of the pharmacodynamics of rocuronium and vecuronium during halothane anaesthesia.
Baird, WL; Booth, MG; Bryden, FM; Marsh, B; Robertson, EN, 1992
)
0.52
" The pharmacokinetic profile was affected by age, sex and anaesthetic technique."( Effect of age, sex and anaesthetic technique on the pharmacokinetics of atracurium.
Hunter, JM; Parker, CJ; Snowdon, SL, 1992
)
0.28
" The elimination half-life (t1/2 beta) was 21."( The pharmacokinetics and locomotor activity of alfentanil in the horse.
Black, WD; Claxton, JM; Pascoe, PJ; Sansom, RE, 1991
)
0.28
" Pharmacokinetic variables were calculated by iterative linear least square regression analysis."( The pharmacodynamics and pharmacokinetics of Org 9426, a new non-depolarizing neuromuscular blocking agent, in patients anaesthetized with nitrous oxide, halothane and fentanyl.
Agoston, S; Kleef, UW; Kloppenburg, WD; Lambalk, LM; Wierda, JM, 1991
)
0.48
" The mean half-life of the tracer in the lungs in Groups I-IV was 60, 58, 59 and 26 min, respectively."( Pulmonary clearance of 99mTc-DTPA during halothane anaesthesia.
Bakker, W; Bos, JA; Krenning, EP; Lachmann, B; Schairer, W; Wollmer, P, 1990
)
0.54
"0 min) infusion of atracurium was administered until twitch tension was suppressed by approximately 70%, and atracurium plasma concentration and twitch tension data were used to determine pharmacokinetic and pharmacodynamic parameters for each patient."( Pharmacokinetics and pharmacodynamics of atracurium in the elderly.
Caldwell, JE; Canfell, PC; Fahey, MR; Fisher, DM; Heier, T; Kitts, JB; Miller, RD; Spellman, MJ, 1990
)
0.28
" The pharmacokinetic parameters derived by compartmental modelling were (normal vs."( The influence of renal failure on the pharmacokinetics and duration of action of pipecuronium bromide in patients anesthetized with halothane and nitrous oxide.
Caldwell, JE; Canfell, PC; Castagnoli, KP; Fahey, MR; Fisher, DM; Lynam, DP; Miller, RD, 1989
)
0.48
" The elderly can show greater sensitivity to opioid drugs which may be related to pharmacokinetic differences."( The pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patients.
Bower, S; Dodson, ME; Kent, AP, 1988
)
0.27
" During neuroleptanalgesia, droperidol kinetics were linear over the dose range tested: the overall mean elimination half-life was 127 min, Vdss 103 litre and the plasma clearance 732 ml min-1."( Pharmacokinetics of droperidol in surgical patients under different conditions of anaesthesia.
Gasparini, R; Heykants, J; Ikonomakis, M; Lehmann, KA; Van Peer, A, 1988
)
0.27
" Using a crossover design, pharmacokinetic values after a single IV dose of gentamicin (4 mg/kg) were compared in halothane-anesthetized and unanesthetized horses."( Effects of halothane anesthesia on the clearance of gentamicin sulfate in horses.
Baggot, JD; Dunlop, CI; Farver, TB; Smith, CM; Steffey, EP, 1988
)
0.88
" Inhalational agents currently in use have acceptable pharmacokinetic characteristics, and clinical acceptance depends on their potential for adverse effects."( Clinical pharmacokinetics of the inhalational anaesthetics.
Brown, BR; Dale, O, 1987
)
0.27
"0% enflurane in air resulted in a 173 and a 206% increase, respectively, in antipyrine plasma half-life and a 29."( Effect of inhalation anesthetics on antipyrine pharmacokinetics of mice.
Kooistra, KL; Moses, CJ; Powis, G; Van Dyke, RA, 1987
)
0.27
" A systematic approach to determine the appropriate dosage for arbitrary flows on the basis of pharmacokinetic models and to adjust the parameters of the model to the individual patient is described."( [Optimization of the dosage of volatile anesthetics based on pharmacokinetic and dynamic models].
Schwilden, H, 1985
)
0.27
" Paracetamol, the only metabolised drug which is conjugated for which pharmacokinetic parameters have been accurately determined in obesity, undergoes increased clearance in obese subjects."( Pharmacokinetics of drugs in obesity.
Abernethy, DR; Greenblatt, DJ,
)
0.13
" The elimination half-life (t beta 1/2) was 174 +/- 60 min in neonates, significantly longer than the values of 90 +/- 23 and 89 +/- 18 min in children and adults, respectively."( Pharmacokinetics and pharmacodynamics of d-tubocurarine in infants, children, and adults.
Cronnelly, R; Fisher, DM; Gregory, GA; Miller, RD; O'Keeffe, C; Stanski, DR, 1982
)
0.26
" Pharmacokinetic analysis showed no significant differences for rocuronium during the 3 anesthetic techniques."( Clinical pharmacology of rocuronium (Org 9426): study of the time course of action, dose requirement, reversibility, and pharmacokinetics.
Hennis, PJ; Leclercq, MG; Smeulers, NJ; van den Broek, L; van Santen, GJ; Wierda, JM,
)
0.13
" The mean elimination half-life was short (15."( Propofol as an induction agent in the goat: a pharmacokinetic study.
Nolan, AM; Reid, J; Welsh, E, 1993
)
0.29
" The elimination half-life was long in both groups (90."( The effects of halothane and nitrous oxide on the pharmacokinetics of propofol in dogs.
Grant, S; Nolan, AM; Reid, J, 1993
)
0.64
"We investigated the pharmacodynamic effects of the phosphodiesterae inhibitor enoximone in the presence of halothane and isoflurane in 20 patients, ASA class III, aged 45-75 years, undergoing coronary artery bypass grafting."( [Pharmacodynamic effects of the phosphodiesterase inhibitor enoximone during exposure to the volatile anesthetics halothane and isoflurane in coronary surgery patients].
Bauch, U; Larsen, R; Molter, G; Peters, U; Sefrin, R, 1993
)
0.71
" A four-parameter threshold pharmacodynamic model was fitted to the data in each patient."( Effect of age, gender and anaesthetic technique on the pharmacodynamics of atracurium.
Hunter, JM; Parker, CJ; Snowdon, SL, 1993
)
0.29
" The overall mean elimination half-life was 182 min, Vdss 169 l and the plasma clearance 910 ml min-1."( Pharmacokinetics of sufentanil in general surgical patients under different conditions of anaesthesia.
Gasparini, R; Lehmann, KA; Sipakis, K; van Peer, A, 1993
)
0.29
" Pharmacokinetic data were analyzed by model-independent methods."( The pharmacokinetics of droperidol in anesthetized children.
Bartkowski, RR; Grunwald, Z; Schieren, H; Torjman, M, 1993
)
0.29
" A two-exponential equation was used to describe the pharmacokinetic data."( Pharmacokinetics of rocuronium after bolus and continuous infusion during halothane anaesthesia.
Maddineni, VR; McCoy, EP; Mirakhur, RK; Proost, JH; Wierda, JM, 1996
)
0.52
"The goal of this study was to develop a human physiologically based pharmacokinetic (PBPK) model for the chemical HCFC-123 (2,2-dichloro-1,1,1-trifluoroethane) and its major metabolite, trifluoroacetic acid (TFA)."( Rat to human extrapolation of HCFC-123 kinetics deduced from halothane kinetics: a corollary approach to physiologically based pharmacokinetic modeling.
Fisher, JW; Jarabek, AM; McDougal, JN; Vinegar, A; Williams, RJ, 1996
)
0.54
" A physiologically based pharmacokinetic model describing the concentration-dependent reduction in uptake and metabolism of halothane in male and female rats was developed."( Physiologically based pharmacokinetic analysis of the concentration-dependent metabolism of halothane.
Anders, MW; Loizou, GD; Tran, CL, 1997
)
0.72
" Marker dispositions were described by recirculatory pharmacokinetic models based on frequent early and less frequent later arterial blood samples."( The effect of halothane on the recirculatory pharmacokinetics of physiologic markers.
Avram, MJ; Gentry, WB; Henthorn, TK; Klein, C; Krejcie, TC; Niemann, CU; Shanks, CA, 1997
)
0.66
" Recirculatory pharmacokinetic models include the best aspects of traditional compartmental and physiologic pharmacokinetic models while offering advantages over both."( The effect of halothane on the recirculatory pharmacokinetics of physiologic markers.
Avram, MJ; Gentry, WB; Henthorn, TK; Klein, C; Krejcie, TC; Niemann, CU; Shanks, CA, 1997
)
0.66
"To determine pharmacokinetic variables of mivacurium chloride after IV administration in dogs."( Pharmacokinetic variables of mivacurium chloride after intravenous administration in dogs.
Cook, DR; Looney, AL; Moon, PF; Schwark, WS; Smith, LJ, 1999
)
0.3
"024 L/kg, median half-life was 34."( Pharmacokinetic variables of mivacurium chloride after intravenous administration in dogs.
Cook, DR; Looney, AL; Moon, PF; Schwark, WS; Smith, LJ, 1999
)
0.3
"The transtrans and cis-trans isomers of mivacurium have a long half-life and slow clearance in healthy dogs anesthetized with halothane."( Pharmacokinetic variables of mivacurium chloride after intravenous administration in dogs.
Cook, DR; Looney, AL; Moon, PF; Schwark, WS; Smith, LJ, 1999
)
0.51
"To determine pharmacodynamic effects and safety of mivacurium in paediatric patients."( [Pharmacodynamics and safety of mivacurium in infants and children under halothane-nitrous oxide anesthesia].
Ecoffey, C; Goujard, E; Meistelman, C; Orliaguet, G; Plaud, B, 1999
)
0.54
"In order to bridge the gap of action of dl-sotalol between the human ether-a-go-go-related gene (hERG) K(+) channel inhibition in vitro and QT-interval prolongation in vivo, its electropharmacological effect and pharmacokinetic property were simultaneously studied in comparison with those of 10 drugs having potential to prolong the QT interval (positive drugs: bepridil, haloperidol, dl-sotalol, terfenadine, thioridazine, moxifloxacin, pimozide, sparfloxacin, diphenhydramine, imipramine and ketoconazole) and four drugs lacking such property (negative drugs: enalapril, phenytoin, propranolol or verapamil) with the halothane-anesthetized guinea pig model."( Why Can dl-Sotalol Prolong the QT Interval In Vivo Despite Its Weak Inhibitory Effect on hERG K(+) Channels In Vitro? Electrophysiological and Pharmacokinetic Analysis with the Halothane-Anesthetized Guinea Pig Model.
Ando, K; Cao, X; Honda, A; Izumi-Nakaseko, H; Katagi, J; Nakamura, Y; Ohara, H; Sugiyama, A, 2016
)
0.78
"In order to better understand the variability of pharmacodynamic and pharmacokinetic profiles of terfenadine between the previous studies as well as to qualitatively and quantitatively examine the proarrhythmic potential of its major active metabolite fexofenadine in comparison with that of terfenadine, we directly compared their electropharmacological effects with halothane-anesthetized dogs (n = 3)."( Comparison of electropharmacological effects between terfenadine and its active derivative fexofenadine using a cross-over study in halothane-anesthetized dogs to analyze variability of pharmacodynamic and pharmacokinetic profiles of terfenadine and torsa
Ando, K; Chiba, K; Goto, A; Hagiwara-Nagasawa, M; Harada, H; Inamura, N; Izumi-Nakaseko, H; Lubna, NJ; Miyamoto, H; Naito, AT; Nakamura, Y; Sugiyama, A; Takagi, K, 2018
)
0.85
" This review lists the individual chiral phases (chiral selectors) used in the enantioseparation as well as in pharmacokinetic studies."( General inhalational anesthetics - pharmacodynamics, pharmacokinetics and chiral properties.
Markuliak, RČLHM, 2021
)
0.62

Compound-Compound Interactions

Myocardial and systemic effects of isovolemic hemodilution alone and combined with controlled hypotension induced with sodium nitroprusside (SNP) were studied in halothane-anesthetized, open-chest dogs. The study was designed to examine the effects of low, moderate, and high doses of propofol on the rate of CSF formation and resistance to reabsorption.

ExcerptReferenceRelevance
"5 minutes of anesthesia with halothane or enflurane combined with nitrous oxide and oxygen."( Recovery, psychomotor skills, and simulated driving after brief inhalational anesthesia with halothane or enflurane combined with nitrous oxide and oxygen.
Blomgren, E; Ertama, P; Häkkinen, S; Korttila, K; Pfäffli, P; Tammisto, T, 1977
)
0.77
"Pre- and peroperative determination of glomerular filtration rate (GFR) was performed in nine patients operated during light halothane anaesthesia (group A) and in nine patients operated during epidural analgesia in combination with light halothane anaesthesia (group B)."( Glomerular filtration rate during halothane anaesthesia and epidural analgesia in combination with halothane anaesthesia.
Berthelsen, P; Bröchner-Mortensen, J; Jensen, BH, 1977
)
0.74
"Myocardial and systemic effects of isovolemic hemodilution alone and combined with controlled hypotension induced with sodium nitroprusside (SNP) were studied in halothane-anesthetized, open-chest dogs."( Myocardial and systemic hemodynamics during isovolemic hemodilution alone and combined with nitroprusside-induced controlled hypotension.
Crystal, GJ; Salem, MR, 1991
)
0.48
"1% end-tidal concentration) combined with epidurally administered morphine were compared during controlled ventilation in 10 dogs used on 2 occasions and randomly allocated to 2 groups."( Comparison of the hemodynamic effects of halothane alone and halothane combined with epidurally administered morphine for anesthesia in ventilated dogs.
Cockshutt, JR; Dyson, DH; McDonell, WN; Valliant, AE; Valverde, A, 1991
)
0.55
" However, when propranolol was combined with the lower levels of verapamil or diltiazem, the result was decreased heart rate, blood pressure, left ventricular maximum rate of tension development (dP/dt), and cardiac index with increased systemic vascular resistance."( The cardiovascular and adrenergic actions of verapamil or diltiazem in combination with propranolol during halothane anesthesia in the dog.
Fung, DM; Kapur, PA; Matarazzo, DA; Sullivan, KB, 1987
)
0.49
" Several anaesthetic agents, often used in combination with fentanyl, were tested with respect to their influence on fentanyl metabolism."( [Biotransformation of fentanyl. II. Acute drug interactions in rats and men (author's transl)].
Daub, D; Heinrich, C; Hunger, L; Lehmann, KA; Weski, C, 1982
)
0.26
" VS under halothane anaesthesia combined with hypoxia or respiratory acidosis did not decrease the cardiovascular parameters as much as VS under halothane anaesthesia alone."( Effect of supramaximal vagal stimulation in combination with hypoxia, respiratory acidosis and deep halothane anaesthesia on cardiovascular function in dogs.
Bastron, RD; Korttila, K, 1982
)
0.88
" Drug-drug interactions are further implicated through this study."( Cerebral blood flow effects of sumatriptan in drug combinations in the baboon model.
Dormehl, IC; Hugo, N; Oliver, DW, 1995
)
0.29
" The present study was designed to examine the effects of low, moderate, and high doses of propofol, given with either fentanyl or halothane, on the rate of CSF formation and resistance to reabsorption of CSF."( Propofol combined with halothane or with fentanyl/halothane does not alter the rate of CSF formation or resistance to reabsorption of CSF in rabbits.
Artru, AA, 1993
)
0.8
" The use of high resolution fluorescence microscopy methods in combination with spatio-temporal mathematical models allows the effects of volatile anesthetics on functional clusters of ryanodin receptors in mammalian skeletal muscle fibers to be studied in situ for the first time."( [High resolution fluorescence microscopy in combination with mathematical modelling. First evidence of sub-cellular anesthetic effects on Ca2+ sparks in situ].
Both, M; Fink, RH; Graf, BM; Martin, E; Sinner, B; Uttenweiler, D; Zink, W, 2003
)
0.32
"1%, preoperatory, if the general anesthesia must be combined with local anesthesia, anesthetics in association with adrenalin should not be used; immediately postoperatory local use of atropine should be applied with cautiousness."( [Neosynephrine mydriasis combined with general anesthesia with halothane in ocular surgery].
Giuri, S, 2002
)
0.55
"The observation of cardiovascular response at peri-extubation period after continuous epidural anesthesia combined with mild general anesthesia was studied."( The observation of response to cardiovascular system at periextubation period after continuous epidural anesthesia combined with general anesthesia.
Lamichhane, N; Prasai, A; Xiang, ZG; Yind, XK, 2003
)
0.32
"The purpose of this study was to evaluate the pharmacokinetics of morphine in combination with dexmedetomidine and maropitant injected intramuscularly in dogs under general anaesthesia."( Pharmacokinetics of morphine in combination with dexmedetomidine and maropitant following intramuscular injection in dogs anaesthetized with halothane.
Chambers, P; Karna, SR; Kongara, K; Singh, P, 2020
)
0.76
" Although considered safe, VA exposure can cause different adverse effects and, in combination with ionising radiation (IR), can also cause synergistic effects."( Different damaging effects of volatile anaesthetics alone or in combination with 1 and 2 Gy gamma-irradiation
Benković, V; Borojević, N; Brozović, G; Knežević, AH; Milić, M; Oršolić, N, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
"The effect of the pH of the solution on the rate of absorption into the blood stream of locally-injected adrenaline using an adrenaline solution mixed with either mepivacaine or bupivacaine was investigated."( Adrenaline absorption: effect of pH in mepivacaine and bupivacaine solutions. A clinical study during halothane anesthesia.
Hirakawa, M; Mori, K; Ueda, W, 1992
)
0.5
" At the end of exposures lasting 3 hr, distribution of halothane in tissues indicated that the bioavailability of halothane in liver was unaffected by exposure to isoflurane."( Inhibitory effect of isoflurane upon oxidative metabolism of halothane.
Fiserova-Bergerova, V, 1984
)
0.76
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The effect of halothane on iontophoretic AMPA dose-response curves was tested. The drug prevented initiation of the MH syndrome in four of eight pigs and attenuated its progress in the remainder. Reproducible shifts in the dose- response of skeletal muscle are the basis of the current in vitro caffeine-halothane contracture test.

ExcerptRelevanceReference
" Ouabain dosage needed to cause ventricular tachycardia was significantly higher than that of pentobarbital with all agents except fluroxene, as was the LD50."( The effect of enflurane, isoflurane, fluroxene, methoxyflurane and diethyl ether anesthesia on ouabain tolerance in the dog.
Albrecht, RF; Cairoli, VJ; El-Etr, AA; Grossman, RK; Ivankovich, AD; Miletich, DJ,
)
0.13
" The two drugs caused comparable shifts of the isoproterenol dose-response curve during anesthesia."( Interaction of anesthesia, beta-receptor blockade, and blood loss in dogs with induced myocardial infarction.
Bennett, MJ; Clarke, TN; Foëx, P; Prys-Roberts, C; Roberts, JG; Ryder, WA, 1976
)
0.26
" When the data were normalized for anesthetic potency, all agents exhibited a parallel dose-response curve."( In vitro inhibition of rho-aminohippurate transport by halogenated anesthetics.
Bastron, RD; Kaloyanides, GJ; Perkins, FM, 1977
)
0.26
" The dose-response curves in all anesthetics remained unaltered in the presence of either 3 x 10(-7) M dl-propranolol or 1 x 10(-6) M atropine."( Mechanisms of chronotropic effects of volatile inhalation anesthetics.
Krisna, G; Paradise, RR,
)
0.13
"There has been no description of the hemodynamic dose-response relationship between halothane and sodium nitroprusside (SNP), although these drugs are used together frequently for induction of deliberate hypotension."( Increasing halothane concentrations reduce nitroprusside dose requirement.
Bedford, RF,
)
0.75
" We conclude this to be the result of limited dosage and maintenance of adequate ventilation and oxygenation."( Topical application of epinephrine during bronchoscopy in barbiturate-halothane-anaesthesia and its influence on cardiac action.
Abel, H; Mall, W,
)
0.37
" The pressure and anaesthetic effects were synergistic with the halothane dose-response curve being shifted to the left and increased in slope at the high pressure, although high pressure alone had no significant effect."( Pressure enhancement of the depressant effect of halothane on cilial beat.
Halsey, MJ; Jones, AJ; Nunn, JF; Pope, WD, 1978
)
0.75
" Previous studies of the effect of halothane on the ATPase of contractile protein suffered from design and dosing defects."( Halothane decreases actomyosin ATPase activity: a possible mechanism of the negative inotropic effect.
Honig, CR; Kumazawa, T; Merin, RG, 1975
)
1.97
"A cumulative dose-response curve for d-tubocurarine based on body weight was determined for 44 infants and children 1 day to 7 years of age during halothane, nitrous oxide and oxygen anesthesia."( Re-evaluation of dosage and duration of action of d-tubocurarine in the pediatric age group.
Donlon, JV; Goudsouzian, NG; Ryan, JF; Savarese, JJ, 1975
)
0.45
" To evaluate this possibility, the authors devised a technique for determining the minimal arrhythmic dosage of epinephrine that permitted graded assessment of changes in the sensitivity of the heart to epinephrine-induced arrhythmias."( Effects of pharmacologic alterations of adrenergic mechanisms by cocaine, tropolone, aminophylline, and ketamine on epinephrine-induced arrhythmias during halothane-nitrous oxide anesthesia.
Koehntop, DE; Liao, JC; Van Bergen, FH, 1977
)
0.45
")Key workd: Potency, anesthetic, MAC, AD50, AD95; Pharmacology, dose-response curves."( MAC expanded: AD50 and AD95 values of common inhalation anesthetics in man.
de Jong, RH; Eger, EI, 1975
)
0.25
"The arrhythmogenic dosage of epinephrine, administered by constant intravenous infusion, was measured in five dogs during enflurane, methoxyflurane and halothane anaesthesia."( Doses of epinephrine causing arrhythmia during enflurane, methoxyflurane and halothane anaesthesia in dogs.
Munson, ES; Tucker, WK, 1975
)
0.68
"The protection against bradycardia afforded by atropine given intravenously just prior to a second dose of suxamethonium during halothane inhalation anaesthesia was studied in 100 healthy, adult patients randomly allocated to one of five groups characterized by dosage of atropine."( Halothane anaesthesia and suxamethonium III. Atropine 30 s before a second dose of suxamethonium during inhalation anaesthesia: effects and side-effects.
Brandt, MR; Viby-Mogensen, J, 1978
)
1.91
" In terms of the chronotropic effect, this dose of metoprolol produced a substantial shift to the right of the dose-response curve to isoprenaline; substantial reductions of arterial pressure (10%), cardiac output (21%), aortic blood acceleration (13%), left ventricular dP/dt max (13%) and left ventricular power (25%) were observed."( Effects of metoprolol on systemic haemodynamics, myocardial performance and the coronary circulation during halothane anaesthesia.
Burt, G; Foëx, P, 1979
)
0.47
" Examination of the complete dose-response curve provided the best comparative information and caffeine was the consistent predictor of susceptibility."( Muscle contractures and adenosine triphosphate depletion in porcine malignant hyperthermia.
Gronert, GA,
)
0.13
"Five anesthetic agents (C1744, etorphine, fentanyl, ketamine hydrochloride, and halothane) were tested to establish the dosage of a safe, effective, short-acting anesthetic for use in the sea otter."( Comparison of anesthetic agents in the sea otter.
Kocher, FH; Williams, TD, 1978
)
0.49
" The shapes of the anesthetic dose-response curves for both CMRO2 and cerebral blood flow (CBF) were examined by multiple measurements made at small, progressive concentration increments from 0 to 2 MAC halothane (six dogs), enflurane (six dogs), and isoflurane (six dogs), and during a constant 23 mg/kg/hr infusion of thiopental (six dogs)."( The nonlinear responses of cerebral metabolism to low concentrations of halothane, enflurane, isoflurane, and thiopental.
Michenfelder, JD; Milde, JH; Stullken, EH; Tinker, JH, 1977
)
0.68
"5 or 23 mmol/kg) and sacrificed 24 h after dosing exhibited liver toxicity."( A study of the mechanism of halothane-induced liver necrosis. Role of covalent binding of halothane metabolites to liver proteins in the rat.
Rao, GS, 1977
)
0.55
" The dosage of halothane with Vapor vaporizer, the reliability of absorption of CO2, the conditions which may be associated with accumulation of nitrogen up to 10 Vol."( [Closed system anaesthesia with continuous inspiratory oxygen measurement (author's transl)].
Spiess, W, 1977
)
0.61
" Compared with basal anesthesia with pentobarbital, 15 mg/kg, neither morphine nor halothane increased sensitivity to any measured effect of propranolol expressed as the slope of the log dose-response relationship."( Failure of general anesthesia to potentiate propranolol activity.
Bragg, DA; Edmonds, CH; Hibbs, CW; Keats, AS; Slogoff, S, 1977
)
0.48
" Consistent results have been obtained with a dosage related to the metabolic rate of the child."( Anaesthesia for electrocochleography.
Hutton, JN, 1976
)
0.26
" A dose-response curve was obtained over a concentration range to as much as 5 vol per cent halothane."( Halothane and the beating response and ATP turnover rate of heart cells in tissue culture.
Hartzell, CR; McCarl, RL; Stong, LJ, 1975
)
1.92
" In addition our results suggest that dosage of morphine and morphine blood levels might also modify norepinephrine excretion."( The effects of morphine and halothane anaesthesia on urine norepinephrine during surgery for congenital heart disease.
Lathrop, GD; Liu, WS; Stanley, TH, 1976
)
0.55
"Cumulative d-tubocurarine dose-response curves were determined in 35 unpremedicated adult surgical patients."( Duration of halothane anesthesia and neuromuscular blockade with d-tubocurarine.
Crique, M; Eger, EI; Miller, RD, 1976
)
0.63
" Responses were defined in terms of percent depression in first-twitch height and train-of-four response, and the dose-response curves were constructed after probit transformation of the responses."( Pipecuronium-induced neuromuscular blockade during nitrous oxide-fentanyl, enflurane, isoflurane, and halothane anesthesia in surgical patients.
Abdulrazik, E; Naguib, M; Seraj, M, 1992
)
0.5
" The dobutamine infusion dosage (5, 10, 15, and 20 micrograms/kg of body weight/min) was increased at 5-minute intervals."( Parasympathetic influence on the arrhythmogenicity of graded dobutamine infusions in halothane-anesthetized horses.
Hellyer, PW; Light, GS; Swanson, CR, 1992
)
0.51
" These vessels were subsequently constricted with K+, and relaxation dose-response curves were obtained for both halothane and isoflurane."( A comparison of the vasodilating effects of halothane and isoflurane on the isolated rabbit basilar artery with and without intact endothelium.
Jensen, NF; Kramer, DJ; Leonard, PA; Todd, MM; Warner, DS, 1992
)
0.76
" Cumulative dose-response curves were obtained to methacholine, a receptor-mediated endothelium-dependent dilator; to A23187, a nonreceptor-mediated endothelium-dependent dilator; and to sodium nitroprusside, a direct-acting endothelium-independent dilator before, during, and after inhalational anesthetic exposure."( Halothane, enflurane, and isoflurane attenuate both receptor- and non-receptor-mediated EDRF production in rat thoracic aorta.
Johns, RA; Proctor, GJ; Uggeri, MJ, 1992
)
1.73
" We determined the dose-response relationship of ORG-9426 in 62 children (aged 1-5 yr) during nitrous oxide-halothane anesthesia by means of log-probit transformation and least-squares linear regression of the initial dose and response."( Effects of bolus administration of ORG-9426 in children during nitrous oxide-halothane anesthesia.
Brandom, BW; Cook, DR; Sarner, JB; Woelfel, SK, 1992
)
0.73
" Neither cardiovascular side effects nor signs of histamine release occurred after the injection of both muscle relaxants at our dosage level."( [Comparative studies of atracurium and vecuronium for medium-length surgical procedures in infants and young children].
Grundmann, U; Ismaily, AJ; Kleinschmidt, S; Motsch, J, 1991
)
0.28
"The dose recommendations for atropine in anesthetized children vary, and the dose-response for heart rate has not been defined."( Dose-response for atropine and heart rate in infants and children anesthetized with halothane and nitrous oxide.
Brown, MP; Palmisano, BW; Setlock, MA; Siker, D; Tripuraneni, R, 1991
)
0.51
" Halothane was dosed by chromatography in the three compartments of a bath for isolated organs with a muscular fiber during steady concentrations were given and after wash out."( [Malignant hyperthermia: halothane kinetics in a study model of muscular contraction. Head space determination and comparison with a mathematical model].
Guevart, E; Haguenoer, JM; Imbenotte, M; Theunynck, D, 1991
)
1.49
" In 8 of 13 patients, the dose-response relationship for each anesthetic was determined by administering different concentrations (1, 3, and 5%) of gas mixtures."( Respiratory, laryngeal, and tracheal responses to nasal insufflation of volatile anesthetics in anesthetized humans.
Hiraga, K; Ishikawa, T; Nishino, T; Tanaka, A, 1991
)
0.28
" To ascertain whether test dosing with other agents might be more useful, we sought to determine if and at what dose levels three different intravenous drugs (adrenaline, isoprenaline and 1% lignocaine with 1/200,000 adrenaline) produced an increase in heart rate (HR) in halothane-anaesthetized lambs."( Efficacy of adrenaline, lignocaine-adrenaline and isoprenaline as a test dose in halothane-anaesthetized lambs.
Berde, CB; Desparmet, JF; Hershenson, MB; Lunn, RJ; Schwartz, DC, 1991
)
0.69
" In nine dogs anesthetized with fentanyl and midazolam, halothane dose-response curves (0."( Effects of cardiopulmonary bypass and cardioplegia on regional and global cardiac actions of halothane in dogs.
Hu, WC; Leone, BJ; McRae, RL; Smith, LR; Spahn, DR, 1991
)
0.75
" The dose-response relationship for the action of halothane was examined with etomidate plus varying subanesthetic concentrations of halothane in dogs."( Myocardial epinephrine sensitization with subanesthetic concentrations of halothane in dogs.
Hayashi, Y; Kamibayashi, T; Kuro, M; Sumikawa, K; Yamatodani, A; Yoshiya, I, 1991
)
0.77
" Guaifenesin amplifies the effect of several anaesthetics, which complement one another, allowing the dosage to be decreased and thereby reducing the cardiovascular stress."( [Combination anesthesia in sheep with ketamine-(fentanyl)-guaifenesin (My 301)-laughing gas-halothane].
Blättchen, C; Blümel, G; Brosch, W; Erhardt, W; Roder, J; Schindele, M, 1990
)
0.5
" These doses were based on the assumption that the slope of the dose-response curve during nitrous oxide-opioid anaesthesia would be approximately the same as the slope of the neuromuscular response from the first human studies with mivacurium."( Neuromuscular and cardiovascular effects of mivacurium chloride (BW B1090U) during nitrous oxide-fentanyl-thiopentone and nitrous oxide-halothane anaesthesia.
Abou-Donia, M; Choi, WW; From, RP; Pearson, KS; Sokoll, MD, 1990
)
0.48
" There was no significant difference between the slopes of the HAL and BAL inhalation anesthetic dose-response curves."( Neuromuscular and cardiovascular effects of mivacurium chloride (BW B109OU) during nitrous oxide-narcotic, nitrous oxide-halothane and nitrous oxide-isoflurane anesthesia in surgical patients.
Abou-Donia, M; Choi, WW; From, RP; Pearson, KS; Sokoll, MD, 1990
)
0.49
"We determined the cumulative dose-response relations of pipecuronium in infants and children during nitrous oxidehalothane anesthesia."( Clinical pharmacology of pipecuronium in infants and children during halothane anesthesia.
Brandom, BW; Cook, DR; Dong, ML; Pickle, D; Sarner, JB; Weinberger, MJ, 1990
)
0.72
"% dosage schedule."( [Isoflurane. (Comparison with halothane and fentanyl anesthesia)].
Incze, F; Kozma, R; Vámos, Z, 1990
)
0.57
" Halothane did not influence the cardiovascular response to PHE: there was no dose-response shift for any cardiovascular variable."( Halothane anaesthesia does not modify the cardiovascular response to phenylephrine in man.
Azmy, SS; Grum, DF, 1990
)
2.63
" Salbutamol did not influence the caffeine dose-response curves in any of the groups (n = 14 in the MH-non-susceptible (MHN) group)."( Influence of salbutamol on the in vitro muscle response to caffeine and halothane in malignant hyperthermia.
Bendixen, D; Ording, H, 1990
)
0.51
" 1, the relative importance of dose level and dosing regimen was examined."( Long-term effects of developmental halothane exposure on radial arm maze performance in rats.
Bowman, RE; DeLuna, R; Levin, ED; Uemura, E, 1990
)
0.56
" Gangliosides, which had no effect per se, showed a clear dose-response relationship in enhancing the anti-immobility effect of desipramine."( Gangliosides enhance the anti-immobility response elicited by several antidepressant treatments in mice.
Basso, AM; Córdoba, NE; Molina, VA; Orsingher, OA, 1990
)
0.28
" The N2O dose-response data for each animal were fit by a second-order polynomial equation to estimate the value of a second-order coefficient."( The nonlinear potency of sub-MAC concentrations of nitrous oxide in decreasing the anesthetic requirement of enflurane, halothane, and isoflurane in rats.
Cole, DJ; Drummond, JC; Kalichman, MW; Shapiro, HM, 1990
)
0.49
" In Study II a dose-response curve was established for the potent stimulator (Sin 1) of the enzyme guanylate cyclase."( Endothelium-derived relaxing factor is not responsible for inhibition of hypoxic pulmonary vasoconstriction by inhalational anesthetics.
Marshall, BE; Marshall, C, 1990
)
0.28
" The dose-response curve for the halothane-induced contractures of Ca2(+)-loaded skinned fibers was displaced to the left after denervation."( Alterations in the functional properties of skinned fibers from denervated rabbit skeletal muscle.
Suarez-Kurtz, G; Sudo, RT; Trachez, MM, 1990
)
0.56
" The slope of the hemolysis dose-response curve was considerably steeper for halothane than for CTX."( Interactions in red blood cells between fatty acids and either snake venom cardiotoxin or halothane.
Beech, J; Fletcher, JE; Jiang, MS; Smith, LA; Tripolitis, L, 1990
)
0.73
" The patient's cardiac insufficiency and chronic bronchitis made a balanced anesthesia with reduced dosage of rapifen and halothane necessary."( [Difficult intubation and anesthesia in Pfaundler-Hurler disease].
Falk, K; Gross, H; Zinganell, K, 1989
)
0.48
"We determined the dose-response relationships of mivacurium (BW B1090U) in children (2-10 years) during nitrous oxide-halothane anesthesia (0."( Clinical pharmacology of mivacurium chloride (BW B1090U) in children during nitrous oxide-halothane and nitrous oxide-narcotic anesthesia.
Brandom, BW; Cook, DR; Dong, ML; Foster, VJ; Horn, MC; McNulty, BF; Sarner, JB; Woelfel, SK, 1989
)
0.71
" In nine children the incremental technique was used to establish a cumulative dose-response curve by train-of-four stimulation."( Neuromuscular and cardiovascular effects of doxacurium in children anaesthetized with halothane.
Alifimoff, JK; Foster, V; Goudsouzian, NG; Liu, LM; McNulty, B; Savarese, JJ, 1989
)
0.5
"The dose-response of pipecuronium bromide, the time course of its neuromuscular blocking effects, and the reversibility of the residual block by neostigmine and edrophonium have been investigated in patients undergoing various types of anesthesia."( Dose-response relation and time course of action of pipecuronium bromide in humans anesthetized with nitrous oxide and isoflurane, halothane, or droperidol and fentanyl.
Agoston, S; Richardson, FJ; Wierda, JM, 1989
)
0.48
" We conclude that there is no clinical indication that the dosage of atracurium and vecuronium during inhalation anesthesia should be reduced, but the doses of pipecuronium and pancuronium should be reduced when prolonged paralysis is not desired."( Interaction between nondepolarizing neuromuscular blocking agents and inhalational anesthetics.
Agoston, S; Hermans, J; Ket, JM; Koot, HW; Rashkovsky, OM; Swen, J, 1989
)
0.28
" On the other hand enflurane and isoflurane exhibited different dose-response relationships when the uptake of calcium was measured (with a calcium-selective electrode) or the transmembrane electrical potential was monitored (with tetraphenylphosphonium-selective electrode) during ATP synthesis or calcium uptake in anesthetic treated mitochondria."( Effects of halothane, enflurane and isoflurane on some energy-converting functions of isolated rat liver mitochondria.
Branca, D; Scutari, G; Varotto, ML; Vincenti, E,
)
0.52
"In a two-part study, the dose-response relationships of doxacurium chloride (BW A938U) were evaluated during general anesthesia maintained with commonly used anesthetic techniques."( Dose-response relationships of doxacurium chloride in humans during anesthesia with nitrous oxide and fentanyl, enflurane, isoflurane, or halothane.
Dunn, K; Fragen, RJ; Katz, JA; McNulty, B; Rudd, GD; Shanks, CA, 1989
)
0.48
" They were treated uniformly with respect to premedication, anesthesia, venipuncture (cubital), and concentration (1%) and dosage (1 mg/kg) of succinylcholine (SCh)."( [The rate of injection of succinylcholine and onset of neuromuscular action, serum potassium or myoglobin levels. Studies in men during halothane anesthesia].
Braun, J; Kutz, N; Plötz, J; Sommerburg, C, 1989
)
0.48
" The effects were analyzed using quantal dose-response data and comparisons were made using ED50 values for moist desquamation."( Modification of the radiation response of pig skin by manipulation of tissue oxygen tension using anesthetics and administration of BW12C.
Barnes, DW; Hopewell, JW; Nethersell, AB; Sansom, JM; van den Aardweg, GJ, 1989
)
0.28
" Dose-response curves were constructed evaluating the relationship between the duration of balloon inflation versus the percentage of animals with a sustained neurologic deficit."( Halothane, fentanyl/nitrous oxide, and spinal lidocaine protect against spinal cord injury in the rat.
Cole, DJ; Drummond, JC; Shapiro, HM; Zivin, JA, 1989
)
1.72
" A critical LAD-stenosis caused no major changes in the general dose-response pattern of isoflurane but further aggravated the depression of cardiac output and stroke volume induced by increasing concentrations of halothane."( Hemodynamic dose-responses to halothane and isoflurane are different in swine with and without critical coronary artery stenosis.
Gilbert, M; Mori, M; Myhre, ES, 1989
)
0.75
" A dose-response relationship for the effect on the arterial capacitance could not be demonstrated."( Effect of N2O on segmental left ventricular function and effective arterial elastance in pigs when added to a halothane-fentanyl-pancuronium anesthetic technique.
Badenhorst, E; Bolliger, C; Coetzee, A; Fourie, P; Lombard, C; Rebel, A, 1989
)
0.49
" In contrast, propranolol shifted the caffeine dose-response curve to the right and significantly increased the caffeine threshold in the MHS group."( Influence of propranolol on the in vitro response to caffeine and halothane in malignant hyperthermia-susceptible muscle.
Ording, H, 1989
)
0.51
" In cat papillary muscle the dose-response relationship appeared upward and to the left as compared to rat atrial preparations and reached a maximal TD increase of around 90%."( Effect of milrinone on ethanol and halothane induced cardiodepression.
Neira, S; Penna, M, 1988
)
0.55
"The purpose of this study was to compare the incremental, cumulative dose method and the single bolus injection technique for construction of dose-response curves for vecuronium."( Dose-response curves for vecuronium during halothane and neurolept anaesthesia: single bolus versus cumulative method.
Engbaek, J; Ording, H; Skovgaard, LT; Viby-Mogensen, J, 1985
)
0.53
" The dose-response curve for vecuronium was determined after the injection of a single bolus (40, 55 or 70 micrograms kg-1) to 33 patients."( Clinical pharmacology of vecuronium in children. Studies during nitrous oxide and halothane in oxygen anaesthesia.
da Silva, GL; Delleur, MM; Loose, JP; Meistelman, C; Saint-Maurice, C, 1986
)
0.5
"25 mg/kg) during anesthesia with O2/N2O/fentanyl, to generate dose-response curves for the relaxants."( The effect of phenytoin on the magnitude and duration of neuromuscular block following atracurium or vecuronium.
Diaz, J; Matteo, RS; Ornstein, E; Schwartz, AE; Silverberg, PA; Young, WL, 1987
)
0.27
" Pressor dose-response curves to the selective alpha 1-adrenergic agonist, phenylephrine, were constructed in groups of rabbits before, during and 2 hr after halothane anesthesia and the dose of phenylephrine that induced a 25 torr increase in mean arterial pressure (ED25) was derived by polynomial regression analysis."( Prolonged hyporesponsiveness of vascular smooth muscle contraction after halothane anesthesia in rabbits.
Hoffman, BB; Maze, M; Smith, CM; Spiss, CK; Tsujimoto, G, 1985
)
0.7
"The minimum anesthetic dose (MAD) and the cardiopulmonary dose-response for halothane were determined in male chickens."( Minimum anesthetic dose and cardiopulmonary dose response for halothane in chickens.
Ludders, JW; Mitchell, GS; Schaefer, SL, 1988
)
0.74
"We were interested in determining the dose-response relationship of atracurium in children (2-10 yr) during nitrous oxide-isoflurane anesthesia (1%) and the atracurium infusion rate required to maintain about 95% neuromuscular blockade during nitrous oxide-halothane (0."( Atracurium infusion requirements in children during halothane, isoflurane, and narcotic anesthesia.
Brandom, BW; Cook, DR; Fehr, B; Lineberry, CG; Rudd, GD; Woelfel, SK, 1985
)
0.7
" Quadratic equations were fitted to the dose-response data by least squares analysis (R2 greater than ."( Comparison of the in vitro myocardial depressant effects of isoflurane and halothane anesthesia.
Bee, DE; Mathew, BP; Neal, MB; Wolf, WJ, 1988
)
0.51
" A practical method for quantitative dosage of volatile anesthetic was derived from this."( Introduction to the quantitative technique of closed circuit anesthesia in dogs.
Moens, Y,
)
0.13
"The induction characteristics, dosage requirements, cardiovascular and respiratory effects of propofol with added lignocaine were compared with those of thiopentone and halothane inhalational induction in two groups of children aged 1-5 years and 5-10 years."( Propofol for induction of anaesthesia in children. A comparison with thiopentone and halothane inhalational induction.
Christie, G; Grant, IS; Gray, IG; Morton, NS; Wee, M, 1988
)
0.69
" In infants 1-6 months old, either dosage of oral atropine preserved HR and SBP as compared with placebo."( Oral atropine premedication in infants attenuates cardiovascular depression during halothane anesthesia.
Friesen, RH; Miller, BR, 1988
)
0.5
"To assess the dose-response effects of isoflurane and halothane anesthesia on hemodynamics and coronary artery reactivity, the authors studied myocardial hyperemic responses following brief single artery flow arrests in 21 open chest, isocapnic swine in which arterial blood pressures and cardiac outputs were recorded."( Comparative coronary vascular reactivity and hemodynamics during halothane and isoflurane anesthesia in swine.
Blomberg, R; Gilbert, M; Mori, M; Roberts, SL; Tinker, JH, 1988
)
0.76
" Then dose-response curves for both muscles were constructed using incremental doses of succinylcholine with an infusion to replace metabolized or redistributing drug."( Potency of succinylcholine at the diaphragm and at the adductor pollicis muscle.
Bevan, DR; Donati, F; Smith, CE, 1988
)
0.27
"The existence of a dose-response relation between nitrous oxide concentration and regional dysfunction in compromised myocardium, and whether or not halothane-induced myocardial depression alleviated this regional dysfunction was examined."( Gradual or abrupt nitrous oxide administration in a canine model of critical coronary stenosis induces regional myocardial dysfunction that is worsened by halothane.
Foëx, P; Lehot, JJ; Leone, BJ; Philbin, DM; Ryder, WA, 1988
)
0.67
"4 nmol and 640 pmol; however, a 64 pmol dosage did not produce significant effects."( Sympatho-adrenal medullary functions in response to intracerebroventricularly injected corticotropin-releasing factor in anesthetized rats.
Kurosawa, M; Sato, A; Swenson, RS; Takahashi, Y, 1986
)
0.27
"Three weeks after dosing male Fischer 344 rats with streptozotocin to induce diabetes, enflurane was administered ip, and 1 h later, fluoride levels were measured in plasma and livers were removed."( Effect of streptozotocin-induced diabetes in the rat on the metabolism of fluorinated volatile anesthetics.
Conney, AH; Pantuck, CB; Pantuck, EJ, 1987
)
0.27
" In the first study, cumulative dose-response curves were constructed in four groups of 10 patients anaesthetized with one of the inhalation agents and nitrous oxide, or with fentanyl and droperidol (control)."( Potentiation of the neuromuscular blockade produced by alcuronium with halothane, enflurane and isoflurane.
Hunter, JM; Keens, SJ; Snowdon, SL; Utting, JE, 1987
)
0.51
"05), thus a parallel shift of the dose-response curves was observed."( Comparison of the effects of halothane on newborn and adult rabbit myocardium.
Krane, EJ; Su, JY, 1987
)
0.56
"The reaction of halothane in subnarcotic dosage (0."( [Does halothane, in subnarcotic dosage, have a detectable broncholytic effect?].
Ebert, C; Gerking, A; Kirsten, D; Paliege, R; Pielesch, W; Precht, B, 1986
)
1.1
" Group B (n = 10), H24 (n = 5), and H72 (n = 5) were anesthetized with sodium thiamylal (B) or halothane and N2O (H24, H72) for 3 h, during which a dose-response curve to histamine was obtained."( Prolonged hyporesponsiveness of airway smooth muscle to histamine following general anesthesia.
Amyot, R; Chapleau, D; Couture, J; Michoud, MC; St-Jean, S, 1986
)
0.49
"To determine if clinical concentrations of halothane have direct relaxant effects on airway smooth muscle, the authors compared dose-response curves to histamine in the control state (thiopental) and during halothane anesthesia (1."( Mode of action of halothane on histamine-induced airway constriction in dogs with reactive airways.
Hirshman, CA; Shah, MV, 1986
)
0.87
" Three dosage rates (10, 30, and 100 ng/kg of body weight/min) were evaluated in each horse."( Cardiopulmonary effects of prostacyclin infusion in anesthetized horses.
Graham, DA; Hardee, GE; Hardee, MM; Moore, JN; Trim, CM, 1985
)
0.27
"0 micrograms/kg/min effectively increased the cardiac output of halothane anaesthetised horses and that dopamine at the high dosage may cause dysrhythmias."( Cardiopulmonary effects of dopamine hydrochloride in anaesthetised horses.
Moore, JN; Trim, CM; White, NA, 1985
)
0.51
" Left ventricular dp/dt and cardiac output were increased in horses given dobutamine at dosage of 3 micrograms/kg/min and in those given either of the drugs at dosages of 5 and 10 micrograms/kg/min."( Hemodynamic responses in halothane-anesthetized horses given infusions of dopamine or dobutamine.
Bednarski, RM; Hubbell, JA; Muir, WW; Skarda, RT; Swanson, CR, 1985
)
0.57
" Thermal damage to liver capsule, liver lobules, portal areas, and central veins did not exhibit monotonic dose-response relationships."( Thermal sensitivity to single and double heat treatments in normal canine liver.
Fajardo, LF; Hahn, GM; Kelly, NI; Nelsen, TS; Prionas, SD; Taylor, MA, 1985
)
0.27
" In general, the averaged sensory-evoked responses from each structure were affected at day 0 of the experiment in dose-response manner, and suppression of the responses was the main effect of halothane."( Prolonged daily inhalation of halothane modifies the dose-response pattern to acute administration of halothane. An electrophysiological study.
Dafny, N; Fuller, GN; Rigor, BM; Wiggins, RC, 1985
)
0.75
"The quantitative aspects of dosing of volatile anaesthetics to establish and maintain constant alveolar concentrations are in general only discussed in the framework of closed circuit anaesthesia."( [Optimization of the dosage of volatile anesthetics based on pharmacokinetic and dynamic models].
Schwilden, H, 1985
)
0.27
" They then compared these dose-response relationships with values obtained for adults (greater than 18 years old) under comparable anesthetic conditions."( Neuromuscular effects of vecuronium (ORG NC45) in infants and children during N2O, halothane anesthesia.
Fisher, DM; Miller, RD, 1983
)
0.49
" Infectious virus and nucleocapsid production were decreased or stopped, depending on the anesthetic dosage used."( Anesthetic action and virus replication: inhibition of measles virus replication in cells exposed to halothane.
Bedows, E; Knight, PR; Nahrwold, ML, 1980
)
0.48
" A sigmoidal dose-response curve was described."( The decrease of the minimum alveolar anesthetic concentration produced by sufentanil in rats.
DiFazio, CA; Engle, JS; Hecker, BR; Lake, CL; Moscicki, JC, 1983
)
0.27
" Thus, inhibition of opiate receptors and endorphins by naloxone in an otherwise clinically effective dosage does not influence the adrenocortical, hyperglycemic, or hemodynamic responses to surgical stress."( Cortisol, glucose, and hemodynamic responses to surgery after naloxone administration.
Blichert-Toft, M; Engquist, A; Hicquet, J; Saurbrey, N, 1981
)
0.26
" An increase in the naloxone dosage (up to 1 mg/kg) was necessary to demonstrate the naloxone antagonistic effect (8-fold increase in the morphine ED50 value) when morphine was given with halothane."( Effect of morphine on the heart rate response to noxious stimulation: interaction with halothane and naloxone.
Kerr, RC; Kissin, I; Smith, RL, 1984
)
0.68
"Pancuronium bromide was administered to calves to define the dosage level necessary to produce surgical relaxation (90% to 99% reduction of base-line evoked, hindlimb digital-extensor muscle twitch tension)."( Neuromuscular and cardiovascular effects of pancuronium bromide in calves anesthetized with halothane.
Hildebrand, SV; Howitt, GA, 1984
)
0.49
" Dosage levels were determined by giving small increments (0."( Dosage requirement of pancuronium in halothane-anesthetized ponies: a comparison of cumulative and single-dose administration.
Hildebrand, SV; Howitt, GA, 1984
)
0.54
" Except for a greater respiratory gas flow and inspiratory-expiratory gas flow ratio and a lesser inspiratory-expiratory time ratio with methoxyflurane, there was no anesthetic- or dose-response effect on respiratory variables."( Circulatory and respiratory effects of methoxyflurane in dogs: comparison of halothane.
Farver, TB; Steffey, EP; Woliner, MJ, 1984
)
0.5
" Safeguards to prevent accidental anesthetic overdosage and algorithms to provide for dosage changes based on patient response were written into the program."( Computer-controlled anesthetic delivery system.
Hall, SM; Lampert, BA; MacKrell, TN; McClure, A, 1984
)
0.27
" Adjustments in anesthetic dosage may be necessary in patients receiving verapamil."( Verapamil decreases MAC for halothane in dogs.
Kates, RE; Mason, DM; Maze, M, 1983
)
0.56
"Cumulative dose-response curves of suxamethonium, tubocurarine, and pancuronium were constructed in 142 patients under enflurane and halothane anesthesia, and neuroleptic anesthesia (control group)."( Differential increase in potency of neuromuscular blocking agents by enflurane and halothane.
Schuh, FT, 1983
)
0.69
"Succinylcholine was administered by infusion to halothane-anesthetized ponies to determine dosage requirements for surgical relaxation up to 3 hours' duration."( Succinylcholine infusion associated with hyperthermia in ponies anesthetized with halothane.
Hildebrand, SV; Howitt, GA, 1983
)
0.75
" We conclude that epinephrine, dopamine, and dobutamine are capable of producing cardiac arrhythmias in vagotomized and nonvagotomized thiamylal-halothane anesthetized dogs and that bilateral vagotomy decreases the dosage of epinephrine, dopamine, and dobutamine required to produce cardiac arrhythmias."( Arrhythmogenicity of dopamine, dobutamine, and epinephrine in thiamylal-halothane anesthetized dogs.
Bednarski, RM; Muir, WW, 1983
)
0.7
"1 The tetanic and single twitch responses to the adductor pollicis muscle were used to study the neuromuscular effects of repeated dosage of decamethonium in nine anaesthetized patients."( Tachyphylaxis after repeated dosage of decamethonium in anaesthetized man.
Al-Azawi, S; Hughes, R; Payne, JP, 1982
)
0.26
" The danger of inferring an effect at clinical concentrations from data obtained at much higher levels is illustrated by a statistical analysis of our dose-response curves."( Do clinical levels of general anaesthetics affect lipid bilayers? Evidence from Raman scattering.
Kovalycsik, M; Lieb, WR; Mendelsohn, R, 1982
)
0.26
"125 mg/kg, however, the dose-response curve was not parallel to those for neostigmine or pyridostigmine."( Edrophonium: duration of action and atropine requirement in humans during halothane anesthesia.
Cronnelly, R; Miller, RD; Morris, RB, 1982
)
0.5
" Ketamine was found to have little effect at the dosage used while halothane proved to be a rapid induction agent providing a safe, continued level of surgical anaesthesia."( Anesthetization of a Cape fur seal (Arctocephalus pusillus) for the treatment of a chronic eye infection and amputation of a metatarsal bone.
Barrow, S; Downes, SJ; Thurman, GD, 1982
)
0.5
" The combination was given in a dosage that produced values for systemic blood pressure, heart rate, and maximal positive left-ventricular dP/dt (LV dP/dt) that were similar to those produced by halothane."( Treatment of myocardial ischemia with halothane or nitroprusside-propranolol.
Bainton, CR; Gerson, JI; Hickey, RF, 1982
)
0.72
"This study was undertaken to examine the dose-response effects of clinical concentrations of halothane on activity of wide-dynamic-range (WDR) neurons in the dorsal horn of the spinal cord of the decerebrate, spinal cord-transected cat."( Effects of halothane on spinal neuronal responses to graded noxious heat stimulation in the cat.
Collins, JG; Homma, E; Kikuchi, H; Kitahata, LM; Namiki, A; Thalhammer, JG, 1980
)
0.87
" Dose-response curves of NOS activity versus anesthetic concentration were constructed."( Selective anesthetic inhibition of brain nitric oxide synthase.
Breslow, MJ; Martin, LD; Tobin, JR; Traystman, RJ, 1994
)
0.29
" This study examined the dose-response relation and receptor-effector mechanisms underlying depression of conduction in canine Purkinje fibers by epinephrine with halothane."( A subtype of alpha 1 adrenoceptor mediates depression of conduction in Purkinje fibers exposed to halothane.
Bosnjak, ZJ; Hoffmann, RG; Kampine, JP; Turner, LA; Vodanovic, S, 1995
)
0.7
"Six dogs were anaesthetized with 1% of halothane-Group I, and six dogs with an equianaesthetic dosage of isoflurane (1."( [Hemodynamic effects of propafenone in dogs anesthesized with halothane or isoflurane].
Castro, G; Figueiredo, F; Fonseca, P; Freitas, M; Godinho, AM; Morais, J; Providência, LA; Viana, Jda S, 1994
)
0.8
" We evaluated dose-response data and neuromuscular effects of 2 x ED95 dose and maintenance doses of 51W89 during halothane anaesthesia in 68 children, 2-12 yr old."( Pharmacodynamic effects of 51W89, an isomer of atracurium, in children during halothane anaesthesia.
Meretoja, OA; Taivainen, T; Wirtavuori, K, 1995
)
0.73
"The dose-response relationship for vecuronium during anesthesia with the azeotropic mixture of halothane and diethyl ether (HE) (66 ml of halothane mixed with 34 ml of ether in the same bottle)/oxygen was compared with halothane/nitrous oxide/oxygen anesthesia."( Halothane-diethyl ether azeotrope anesthesia under primitive conditions: guidelines for neuromuscular blockade with vecuronium.
Bengtsson, M; Eriksson, LI; Kalman, SH; Lennmarken, C, 1993
)
1.95
" Glycopyrrolate was administered IV and IM at a dosage of 11 micrograms/kg of body weight, each."( Alterations in the arrhythmogenic dose of epinephrine after xylazine or medetomidine administration in halothane-anesthetized dogs.
Benson, GJ; Lemke, KA; Olson, WA; Thurmon, JC; Tranquilli, WJ, 1993
)
0.5
"The objective of this study was to determine the dose-response effects of epinephrine, given by systemic intravenous infusion to the halothane-anesthetized newborn piglet, on renal blood flow, mean arterial blood pressure, and renal vascular resistance."( Renal vascular effects of epinephrine infusion in the halothane-anesthetized piglet.
Allen, RG; Barrington, KJ; Dewald, JW, 1994
)
0.74
" In addition, the dose-response relation for halothane on [methyl-3H]choline uptake was studied."( Volatile anesthetic agents inhibit choline uptake into rat synaptosomes.
Boyle, E; Greiff, JM; Griffiths, R; Norman, RI; Rowbotham, DJ, 1994
)
0.55
" It is pointed out that the operation of respirators of this type is safe only provided the prescribed gas supply pressures are observed, if necessary with the help of the appropriate reducing valves, to ensure accurate dosage of volatile anaesthetics."( [Accidental anesthetic overdose caused by anesthesia respirators Servo 900 C and D].
Hemplemann, G; Jung, HJ; Müller, M; Sticher, J; Zeiler, D, 1994
)
0.29
" The preparations were then exposed to up to 4 vol% volatile agent incrementally to generate a cumulative dose-response curve, and the subsequent frequency of peristaltic contractions was determined."( Volatile anesthetics decrease peristalsis in the guinea pig ureter.
Attele, A; Moss, J; Núñez, R; Toledano, A; Young, CJ, 1994
)
0.29
" The myocardial depression cannot be necessarily attenuated by vagolysis regardless of the dosage of atropine."( Echocardiographic evaluation of vagolytic effects of atropine sulfate during pediatric halothane anesthesia.
Hirano, T; Horigome, H; Tsuji, M; Yamashita, M, 1993
)
0.51
"We determined the dose-response relationship of mivacurium in infants 2-6 and 7-11 mo of age during nitrous oxide-halothane anesthesia."( Clinical pharmacology of mivacurium in pediatric patients less than off years old during nitrous oxide-halothane anesthesia.
Brandom, BW; Cook, DR; McGowan, FX; Woelfel, SK, 1993
)
0.71
" We were unable to identify any differences between the two groups with respect to narcotic, benzodiazepine dosage or usage of inhalational agents."( Recall of intraoperative events after general anaesthesia and cardiopulmonary bypass.
Devitt, JH; Harrington, EM; McLean, RF; Phillips, AA, 1993
)
0.29
" This study was designed to evaluate the neuromuscular effects of mivacurium by dose-response analysis, and its cardiovascular effects in 90 infants 2-11 months of age anesthetized with 1% halothane and nitrous oxide:oxygen."( Pharmacodynamic and hemodynamic effects of mivacurium in infants anesthetized with halothane and nitrous oxide.
Denman, W; Foster, V; Goudsouzian, NG; Samara, B; Schwartz, A; Shorten, G, 1993
)
0.7
" The first four doses in each group were used to determine dose-response relationships."( Pharmacodynamic and hemodynamic effects of mivacurium in infants anesthetized with halothane and nitrous oxide.
Denman, W; Foster, V; Goudsouzian, NG; Samara, B; Schwartz, A; Shorten, G, 1993
)
0.51
"6 MAC halothane did not significantly affect the dose-response relationship between isoproterenol and force."( Halothane and pertussis toxin-sensitive G proteins in airway smooth muscle.
Jones, KA; Morimoto, N; Warner, DO; Yamamoto, K, 1994
)
2.21
" After a stable baseline was obtained, dose-response curves to histamine (50, 100, or 200 micrograms intravenous bolus) or hypocapnia (0% CO2 for 2 min with 100, 200, or 400 ml/min collateral flow) were constructed."( Effects of halothane, propofol, and thiopental on peripheral airway reactivity.
Lindeman, KS; Mehr, EH, 1993
)
0.68
" A cumulative log-probit dose-response curve of vecuronium was established."( The neuromuscular blocking effects of vecuronium during sevoflurane, halothane and balanced anaesthesia in children.
Meretoja, OA; Taivainen, T, 1995
)
0.53
"In vitro, prospective, repeated-measures, dose-response study."( Effect of halothane on phenylephrine-induced vascular smooth muscle contractions in endotoxin-exposed rat aortic rings.
Bina, S; Grissom, TE; Hart, J; Muldoon, SM, 1996
)
0.7
" Phenylephrine dose-response data (10(-10) to 10(-5) M) were determined for lipopolysaccharide- and nonlipopolysaccharide-treated rings."( Effect of halothane on phenylephrine-induced vascular smooth muscle contractions in endotoxin-exposed rat aortic rings.
Bina, S; Grissom, TE; Hart, J; Muldoon, SM, 1996
)
0.7
" The present study examined the dose-response effects of halothane on the RV contraction pattern and regional contractility in seven open-chest pigs instrumented for measurement of inflow and outflow tract pressures and segment lengths."( The dose-dependent effects of halothane on right ventricular contraction pattern and regional inotropy in swine.
Heerdt, PM; Pleimann, BE, 1996
)
0.83
" Isoflurane at 1 and 2 MAC concentration, and enflurane at 2 MAC, induced a rightward shift of the dose-response curve obtained with endothelin-1 in both endothelium denuded and intact rings, associated with a decrease in maximal tension generated in the latter rings."( Effects of halothane, enflurane and isoflurane on contraction of rat aorta induced by endothelin-1.
Auclerc, A; Barale, F; Boillot, A; Marty, J; Vallet, B, 1995
)
0.68
" Using the cumulative dose-response technique and electromyography, we determined ED50 and ED90 of doxacurium during halothane (n = 9), isoflurane (n = 12) or alfentanil (n = 9) based anaesthesia in children aged 2-10 years."( Doxacurium pharmacodynamics in children during volatile and opioid-based anaesthesia.
Kern, C; Pittet, JF; Rouge, JC; Tassonyi, E; Wilder-Smith, OH, 1996
)
0.5
" The inhalation of isoflurane, halothane and sevoflurane decreased the airway resistance and systemic vascular resistance in direct relationship to the dosage administered."( [Comparison of the effects of halothane, isoflurane and sevoflurane in the treatment of severe asthmatic attack: a case report].
Arai, K; Fujita, T; Hasegawa, Y; Isa, Y; Kunimoto, F; Ohyama, A, 1996
)
0.87
" Furthermore, given that the PBPK model adequately describes the kinetics of halothane in rats and humans and of HCFC-123 in rats, use of the human PBPK model is proposed for deriving dose-response estimates of human health risks in the absence of human kinetic data."( Rat to human extrapolation of HCFC-123 kinetics deduced from halothane kinetics: a corollary approach to physiologically based pharmacokinetic modeling.
Fisher, JW; Jarabek, AM; McDougal, JN; Vinegar, A; Williams, RJ, 1996
)
0.76
"kg-1), doses in the steep part of the dose-response curve."( Sympatholytic and minimum anesthetic concentration-sparing responses are preserved in rats rendered tolerant to the hypnotic and analgesic action of dexmedetomidine, a selective alpha(2)-adrenergic agonist.
Guo, TZ; Gustafsson, E; Maze, M; Rabin, BC; Reid, K; Zhang, C, 1996
)
0.29
" Postoperative analgesic effects were assessed by the total dosage of pentazocine required for the 48 hr after surgery."( Epidural administered buprenorphine in the perioperative period.
Fukushima, K; Miwa, Y; Yonemura, E, 1996
)
0.29
" Dose-response curves are presented for stepwise increases in stable end-tidal concentrations of each agent."( Quantitative EEG in assessment of anaesthetic depth: comparative study of methodology.
Prior, PF; Thomsen, CE, 1996
)
0.29
" Dose-response curves to topically applied Krebs' solution saturated with halothane at increasing concentrations of 0%, 1%, 3% and 5% were carried out in the presence of an inhibitor of nitric oxide synthesis (N omega-nitro-L-arginine (LNA), 300 mumol litre-1) or inhibitors of prostaglandin synthesis (mefenamic acid 20 mumol litre-1 or indomethacin 20 mol litre-1) or in the absence of any inhibitor."( Role of prostaglandins and nitric oxide on halothane-induced arteriolar dilatation in rat diaphragm.
Aubier, M; Boczkowski, J; de Larminat, V; Desmonts, JM; Dureuil, B; Farinotti, R; Vicaut, E, 1996
)
0.79
"We have analysed the dose-response curve for halothane and isoflurane according to the Monod-Wyman-Changeux (MWC) model."( Dose-response curve for anaesthetics based on the Monod-Wyman-Changeux model.
Imaiand, K; Iwai, T; Kihara, H; Uchida, M, 1996
)
0.55
"To compare dose-response relationship and maintenance requirement of pipecuronium in anesthetized infants, children, and adults."( Pipecuronium revisited: dose-response and maintenance requirement in infants, children, and adults.
Erkola, O; Meretoja, OA, 1997
)
0.3
" An individual cumulative log-probit dose-response curve was established and maintenance requirement of pipecuronium determined."( Pipecuronium revisited: dose-response and maintenance requirement in infants, children, and adults.
Erkola, O; Meretoja, OA, 1997
)
0.3
" After preconstriction with the thromboxane analog, U46619 (9,11-dideoxy-11 alpha, 9 alpha-epoxymethano-prostaglandin F2 alpha), the pulmonary vascular dose-response relationship for the k+ATP agonist lemakalim was assessed in the conscious and halothane-anesthetized states and also in the conscious and enflurane-anesthetized states."( Halothane and enflurane attenuate pulmonary vasodilation mediated by adenosine triphosphate-sensitive potassium channels compared to the conscious state.
Murray, PA; Nakayama, M; Sato, K; Seki, S, 1997
)
1.92
"05) in the lemakalim dose-response relationship."( Halothane and enflurane attenuate pulmonary vasodilation mediated by adenosine triphosphate-sensitive potassium channels compared to the conscious state.
Murray, PA; Nakayama, M; Sato, K; Seki, S, 1997
)
1.74
"Dopexamine has a hemodynamic profile suited to treatment of low cardiac output in anesthetized horses; however, at the dosage rate studied (4 micrograms/kg/min), its administration was associated with a number of undesirable adverse effects which could preclude its clinical use."( Temporal effects of an infusion of dopexamine hydrochloride in horses anesthetized with halothane.
Blissitt, KJ; Clutton, RE; Molony, V; Young, LE, 1997
)
0.52
" MHEh muscles revealed a dose-response curve similar to that found in MHN specimens."( Classification of malignant hyperthermia-equivocal patients by 4-chloro-M-cresol.
Bittner, RE; Fricker, R; Gilly, H; Kress, HG; Musat, I; Steinbereithner, K, 1997
)
0.3
" The dose-response relationship during the pre-anaesthetic and pre-equilibrium state of four inhalation anaesthetics (halothane, enflurane, isoflurane and sevoflurane) on fixed-ratio schedule-controlled behaviour was studied in mice."( Psychomotor performance during initial stage of exposure to halothane, enflurane, isoflurane and sevoflurane in mice.
Komatsu, H; Kuratani, N; Nogaya, J; Ogli, K; Ueki, M; Yokono, S,
)
0.58
" Lemakalim dose-response curves were also generated in rings pretreated with the nitric oxide synthase inhibitor, Nw-nitro-L-arginine methyl ester (L-NAME); the cyclooxygenase inhibitor, indomethacin; or the K+(ATP) channel antagonist, glybenclamide."( Halothane attenuates endothelium-dependent pulmonary vasorelaxant response to lemakalim, an adenosine triphosphate (ATP)-sensitive potassium channel agonist.
Horibe, M; Murray, PA; Seki, S, 1997
)
1.74
"9%) was administered intravenously at a dosage of 1% of body weight immediately after suture removal following a 2-hour period of MCA occlusion."( Effect of delayed albumin hemodilution on infarction volume and brain edema after transient middle cerebral artery occlusion in rats.
Belayev, L; Busto, R; Clemens, JA; Ginsberg, MD; Zhao, W, 1997
)
0.3
" Dose-response curves are presented for stepwise increases in stable end-tidal concentrations of each agent."( [Quantitative EEG in assessment of anesthesia depth. Methods of comparison].
Prior, P; Thomsen, CE, 1998
)
0.3
"Isoproterenol has been suggested as an alternative marker for epidural test dosing in children receiving halothane anesthesia."( Simulation of an epidural test dose with intravenous isoproterenol in sevoflurane- and halothane-anesthetized children.
Glaser, C; Kozek, ME; Kozek-Langenecker, SA; Krenn, CG; Marhofer, P; Semsroth, M, 1998
)
0.74
"Isoproterenol has been suggested as an alternative marker for epidural test dosing in children receiving halothane anesthesia."( Simulation of an epidural test dose with intravenous isoproterenol in sevoflurane- and halothane-anesthetized children.
Glaser, C; Kozek, ME; Kozek-Langenecker, SA; Krenn, CG; Marhofer, P; Semsroth, M, 1998
)
0.74
" The effect of halothane on iontophoretic AMPA dose-response curves was tested."( Presynaptic and postsynaptic actions of halothane at glutamatergic synapses in the mouse hippocampus.
Kirson, ED; Perouansky, M; Yaari, Y, 1998
)
0.92
" Dose-response curves were performed for each drug."( Postcardioplegic myocardial recovery: effects of halothane, nifedipine, HOE 694, and quinacrine.
Genade, S; Lochner, A; Theron, S; Trollip, G; Tromp, E, 1998
)
0.55
"5 microg/kg/min, with further improvement as the dosage increased."( Effects of dopamine, dobutamine, dopexamine, phenylephrine, and saline solution on intramuscular blood flow and other cardiopulmonary variables in halothane-anesthetized ponies.
Alibhai, HI; Clarke, KW; Lee, YH; Song, D, 1998
)
0.5
" When co-administered in low dosage with halothane, the drug prevented initiation of the MH syndrome in four of eight pigs and attenuated its progress in the remainder."( Eltanolone (5-beta-pregnanolone) does not trigger, and attenuates halothane triggering of, malignant hyperthermia in malignant hyperthermia susceptible swine.
Dyer, RA; Harrison, GG; James, MF; Llewellyn, RL, 1999
)
0.81
" The different relative positions of the dose-response curves for EEG and MLAEP changes compared with antinociception (MAC) changes suggest differences in the mechanisms of action of these three agents."( Comparison of the effects of halothane, isoflurane and methoxyflurane on the electroencephalogram of the horse.
Johnson, CB; Taylor, PM, 1998
)
0.59
"We used 2 dosage levels of postoperative opioid administration to determine whether the degree of postoperative analgesia after laparotomy during the last third of baboon pregnancy alters maternal pituitary-adrenal function, androgen secretion, and placental estrogen production."( Level of postoperative analgesia is a critical factor in regulation of myometrial contractility after laparotomy in the pregnant baboon: implications for human fetal surgery.
Abrams, LM; Ding, XY; Giussani, DA; Nathanielsz, PW; Tame, JD; Yen, A, 1999
)
0.3
" However, the dose-response relationship, reproducibility and effect of anesthetic agents on induction are not well understood."( Induction of atrial fibrillation and flutter in dogs using methacholine.
Ross, DL; Thomas, SP, 1999
)
0.3
" When horses were anesthetized with halothane, a higher dosage of calcium gluconate was required to attenuate the depression in stroke index and maximal rate of increase in right ventricular pressure; cardiac index was not changed with calcium administration."( Hemodynamic effects of ionized calcium in horses anesthetized with halothane or isoflurane.
Benson, GJ; Constable, PD; Davis, LE; Foreman, JH; Grubb, TL; Olson, WO; Thurmon, JC; Tranquilli, WJ, 1999
)
0.81
"Although no dose-response relationship for the health risks associated with the occupational exposure to inhaled anaesthetics exists, public health authorities recommend threshold values."( Occupational exposure to inhaled anaesthetics: a follow-up study on anaesthetists of an eastern European university hospital.
Harth, M; Hobbhahn, J; Hoerauf, K; Jurczyk, W; Sobczynski, P; Szulc, R; Taeger, K; Wiesner, G, 2000
)
0.31
"Although no dose-response relationship exists for the health risks associated with the occupational exposure to inhaled anaesthetics, public health authorities recommend threshold values."( A follow-up study on occupational exposure to inhaled anaesthetics in Eastern European surgeons and circulating nurses.
Harth, M; Hobbhahn, J; Hoerauf, KH; Jurczyk, W; Sobczynski, P; Szulc, R; Taeger, K; Wiesner, G, 2001
)
0.31
"Human exposure guidelines for halogenated hydrocarbons (halons) and halon replacement chemicals have been established using dose-response data obtained from canine cardiac sensitization studies."( PBPK modeling of canine inhalation exposures to halogenated hydrocarbons.
Vinegar, A, 2001
)
0.31
" Halothane shifted the ACh dose-response curve for the alpha 4 beta 2-type currents in the direction of lower ACh concentrations and slowed its apparent rate of desensitization."( Modulation of neuronal nicotinic acetylcholine receptors by halothane in rat cortical neurons.
Aistrup, GL; Marszalec, W; Mori, T; Narahashi, T; Nishikawa, K; Yeh, JZ; Zhao, X; Zuo, Y, 2001
)
1.46
" Some of the point mutations caused shifts in the GABA dose-response curve, indicating that the mutations changed the apparent affinity of the receptor for GABA."( Volatile anesthetic actions on the GABAA receptors: contrasting effects of alpha 1(S270) and beta 2(N265) point mutations.
Harrison, NL; Jenkins, A; Nishikawa, K; Paraskevakis, I, 2002
)
0.31
" The family survey and dosage of porphyric compounds in the sickness-bearing patient's family members allow to reveal certain asymptomatic forms of the heriditary acute porphyria, it is caused by certain products used in neuropsychiatry, in aneasthesic or in certain circunstances, such as, the infection or the trauma."( [Fatal postoperative crisis in acute hereditary porphyria].
Abbes, I; Affes, N; Ben Amar, M; Beyrouti, MI; Frikha, MF; Mseddi, MA; Zouari, R, 2002
)
0.31
" However, critical hemoglobin was significantly higher in the animals receiving the higher anesthetic dosage (1."( Tolerance to acute isovolemic hemodilution. Effect of anesthetic depth.
De Hert, S; Degroote, F; Mathieu, N; Schmartz, D; Van der Linden, P; Vincent, JL; Zhang, H, 2003
)
0.32
"000) and the difference was significantly greater in lower dosage of nitroglycerin compared with higher dosage."( Clinical trial of nitroglycerin-induced controlled hypotension with or without acupoint electrical stimulation in microscopic middle ear surgery under general anesthesia with halothane.
Ahmadi, A; Rezvani, M; Saghaei, M, 2005
)
0.52
" Reproducible shifts in the dose-response of skeletal muscle to caffeine and halothane are the basis of the current in vitro diagnostic caffeine-halothane contracture test."( Effects of caffeine, halothane, and 4-chloro-m-cresol on skeletal muscle lactate and pyruvate in malignant hyperthermia-susceptible and normal swine as assessed by microdialysis.
Bina, S; Bünger, R; Cowan, G; Karaian, J; Mongan, P; Muldoon, S, 2006
)
0.88
" MH susceptibility leads to a leftward shift of the dose-response curve for IM lactate after local injection of halothane and caffeine."( The dose-response relationship and regional distribution of lactate after intramuscular injection of halothane and caffeine in malignant hyperthermia-susceptible pigs.
Anetseder, M; Hager, M; Müller, R; Roewer, N; Schöll, H; Schuster, F, 2006
)
0.76
" Our study provides dosing and adverse effect data as a basis for further randomized controlled clinical trials to determine the efficacy of oral dantrolene for symptomatic relief in MHS-related myopathies."( Oral Dantrolene for Myopathic Symptoms in Malignant Hyperthermia-Susceptible Patients: A 25-Year Retrospective Cohort Study of Adverse Effects and Tolerability.
Ibarra Moreno, CA; Jungbluth, H; Kraeva, N; Riazi, S; Voermans, NC; Zvaritch, E, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
inhalation anaestheticnull
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
haloalkaneA halohydrocarbon that is an alkane in which at least one hydrogen atom has been replaced by with a halogen atom.
organofluorine compoundAn organofluorine compound is a compound containing at least one carbon-fluorine bond.
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
organobromine compoundA compound containing at least one carbon-bromine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (8)

PathwayProteinsCompounds
Metabolism14961108
Biological oxidations150276
Phase I - Functionalization of compounds69175
Cytochrome P450 - arranged by substrate type30110
Xenobiotics450
CYP2E1 reactions019
Ethanol metabolism resulting in production of ROS by CYP2E1117
Ethanol metabolism production of ROS by CYP2E1117

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID886
Chain A, CruzipainTrypanosoma cruziPotency39.81070.002014.677939.8107AID1476
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency37.65050.011212.4002100.0000AID1030
estrogen nuclear receptor alphaHomo sapiens (human)Potency67.19700.000229.305416,493.5996AID1259244
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency19.14520.023723.228263.5986AID743222; AID743223
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency74.97800.000627.21521,122.0200AID651741
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency67.19700.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency18.08340.002319.595674.0614AID651631
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency67.19700.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AlbuminHomo sapiens (human)IC50 (µMol)2,900.00000.00131.62173.5000AID203629
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)IC50 (µMol)8,150.00000.00032.25459.6000AID1207655; AID1207656
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (149)

Processvia Protein(s)Taxonomy
cellular response to starvationAlbuminHomo sapiens (human)
negative regulation of mitochondrial depolarizationAlbuminHomo sapiens (human)
cellular response to calcium ion starvationAlbuminHomo sapiens (human)
cellular oxidant detoxificationAlbuminHomo sapiens (human)
transportAlbuminHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
immune system developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
heart developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
embryonic forelimb morphogenesisVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
camera-type eye developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transport into cytosolVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transport via high voltage-gated calcium channelVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cell communication by electrical coupling involved in cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of ventricular cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (48)

Processvia Protein(s)Taxonomy
oxygen bindingAlbuminHomo sapiens (human)
DNA bindingAlbuminHomo sapiens (human)
fatty acid bindingAlbuminHomo sapiens (human)
copper ion bindingAlbuminHomo sapiens (human)
protein bindingAlbuminHomo sapiens (human)
toxic substance bindingAlbuminHomo sapiens (human)
antioxidant activityAlbuminHomo sapiens (human)
pyridoxal phosphate bindingAlbuminHomo sapiens (human)
identical protein bindingAlbuminHomo sapiens (human)
protein-folding chaperone bindingAlbuminHomo sapiens (human)
exogenous protein bindingAlbuminHomo sapiens (human)
enterobactin bindingAlbuminHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (35)

Processvia Protein(s)Taxonomy
extracellular regionAlbuminHomo sapiens (human)
extracellular spaceAlbuminHomo sapiens (human)
nucleusAlbuminHomo sapiens (human)
endoplasmic reticulumAlbuminHomo sapiens (human)
endoplasmic reticulum lumenAlbuminHomo sapiens (human)
Golgi apparatusAlbuminHomo sapiens (human)
platelet alpha granule lumenAlbuminHomo sapiens (human)
extracellular exosomeAlbuminHomo sapiens (human)
blood microparticleAlbuminHomo sapiens (human)
protein-containing complexAlbuminHomo sapiens (human)
cytoplasmAlbuminHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic densityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
dendriteVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic density membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (105)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1207655Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1525564Activation of human TASK1 expressed in African green monkey COS cells at 1 mM by whole cell patch clamp assay relative to control2019Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22
TASK Channels Pharmacology: New Challenges in Drug Design.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID603951In-vitro air to blood partition coefficients of the compound, logK(blood) (human/rat)2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID203629Inhibitory concentration bound to tryptophan containing region of Serum albumin in fluorescence quenching2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
Halogenated diazirines as photolabel mimics of the inhaled haloalkane anesthetics.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1207656Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID112346Evaluated in vitro for anesthetic activity in mice and ED50 value was reported1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Hydrogen bonding and anesthetic potency.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID26047logBB, log(C brain / C blood)1996Journal of medicinal chemistry, Nov-22, Volume: 39, Issue:24
Computation of brain-blood partitioning of organic solutes via free energy calculations.
AID27108Dissociation constant for a single binding site2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
Halogenated diazirines as photolabel mimics of the inhaled haloalkane anesthetics.
AID107968Evaluated in vitro for anesthetic activity in man and minimum alveolar concentration (MAC) was determined1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Hydrogen bonding and anesthetic potency.
AID28398Partition coefficient was determined in oil/gas system and value was reported1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Hydrogen bonding and anesthetic potency.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1654571Drug elimination in human2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Metabolic and Pharmaceutical Aspects of Fluorinated Compounds.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID603952In-vitro blood to lung partition coefficients of the compound, logP(lung) (human/rat)2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID1525577Activation of human TASK1 expressed in African green monkey COS cells at 0.1 to 1 mM by whole cell patch clamp assay relative to control2019Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22
TASK Channels Pharmacology: New Challenges in Drug Design.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1525560Activation of human TASK3 expressed in Xenopus oocytes at 1 mM by whole cell patch clamp assay relative to control2019Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22
TASK Channels Pharmacology: New Challenges in Drug Design.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID23443Partition coefficient (logP)1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
Use of physicochemical parameters in distance geometry and related three-dimensional quantitative structure-activity relationships: a demonstration using Escherichia coli dihydrofolate reductase inhibitors.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID589104Mechanism based inhibition of human cytochrome P450 2E1 measured by chlorzoxazone 6-hydroxylase activity2005Current drug metabolism, Oct, Volume: 6, Issue:5
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID603950In-vitro air to lung partition coefficients of the compound, logK(lung) (human/rat)2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID59016Evaluated in vitro for anesthetic activity in dog and minimum alveolar concentration (MAC) was determined1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Hydrogen bonding and anesthetic potency.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1346588Rat K2P3.1 (Two P domain potassium channels)1998The EMBO journal, Aug-03, Volume: 17, Issue:15
A mammalian two pore domain mechano-gated S-like K+ channel.
AID1346588Rat K2P3.1 (Two P domain potassium channels)2002The Journal of neuroscience : the official journal of the Society for Neuroscience, Feb-15, Volume: 22, Issue:4
Serotonergic raphe neurons express TASK channel transcripts and a TASK-like pH- and halothane-sensitive K+ conductance.
AID1346669Human K2P9.1 (Two P domain potassium channels)2002The Journal of biological chemistry, May-17, Volume: 277, Issue:20
Modulation of TASK-1 (Kcnk3) and TASK-3 (Kcnk9) potassium channels: volatile anesthetics and neurotransmitters share a molecular site of action.
AID1346604Human K2P2.1 (Two P domain potassium channels)1999Nature neuroscience, May, Volume: 2, Issue:5
Inhalational anesthetics activate two-pore-domain background K+ channels.
AID1346668Rat Kv2.1 (Voltage-gated potassium channels)1996Anesthesiology, Apr, Volume: 84, Issue:4
Inhibitory effects of ketamine and halothane on recombinant potassium channels from mammalian brain.
AID1346680Human K2P5.1 (Two P domain potassium channels)2000Anesthesiology, Jun, Volume: 92, Issue:6
Volatile anesthetics activate the human tandem pore domain baseline K+ channel KCNK5.
AID1346658Human K2P13.1 (Two P domain potassium channels)2014The Journal of biological chemistry, Oct-10, Volume: 289, Issue:41
Tandem pore domain halothane-inhibited K+ channel subunits THIK1 and THIK2 assemble and form active channels.
AID1346679Human K2P10.1 (Two P domain potassium channels)2000The Journal of biological chemistry, Sep-15, Volume: 275, Issue:37
Human TREK2, a 2P domain mechano-sensitive K+ channel with multiple regulations by polyunsaturated fatty acids, lysophospholipids, and Gs, Gi, and Gq protein-coupled receptors.
AID1346665Human K2P12.1 (Two P domain potassium channels)2014The Journal of biological chemistry, Oct-10, Volume: 289, Issue:41
Tandem pore domain halothane-inhibited K+ channel subunits THIK1 and THIK2 assemble and form active channels.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12,878)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908819 (68.48)18.7374
1990's2722 (21.14)18.2507
2000's1054 (8.18)29.6817
2010's231 (1.79)24.3611
2020's52 (0.40)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 68.08

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index68.08 (24.57)
Research Supply Index9.63 (2.92)
Research Growth Index4.05 (4.65)
Search Engine Demand Index125.45 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (68.08)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials884 (6.15%)5.53%
Reviews508 (3.54%)6.00%
Case Studies628 (4.37%)4.05%
Observational4 (0.03%)0.25%
Other12,345 (85.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Vasodilation Effect of Inhalational Anesthetics Including Halothane, Isoflurane, Sevoflurane, Desflurane and Enflurane [NCT00815269]300 participants (Actual)Interventional2008-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]